Christopher P. Evans

Title(s)Professor, Urology
SchoolSchool of Medicine
AddressACC/UCDMC
CA 95817
Phone916-734-7520
vCardDownload vCard

    Collapse Research 
    Collapse Research Activities and Funding
    Neurotrophins and Tyrosine Kinases in Prostate Cancer
    NIH/NIDDK K08DK060748Mar 1, 2002 - Nov 30, 2006
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. IGFBP3 promotes resistance to Olaparib via modulating EGFR signaling in advanced prostate cancer. iScience. 2024 Feb 16; 27(2):108984. Leslie AR, Ning S, Armstrong CM, D'Abronzo LS, Sharifi M, Schaaf ZA, Lou W, Liu C, Evans CP, Lombard AP, Gao AC. PMID: 38327800; PMCID: PMC10847745.
      View in: PubMed   Mentions:
    2. Secondary Bladder Cancer After Prostate Cancer Treatment: An Age-matched Comparison Between Radiation and Surgery. Eur Urol Focus. 2023 Sep 16. Monda S, Pratsinis M, Lui H, Noel O, Chandrasekar T, Evans CP, Dall'Era MA. PMID: 37722954.
      View in: PubMed   Mentions: 2     Fields:    
    3. The Genomic and Epigenomic Landscape of Double-Negative Metastatic Prostate Cancer. Cancer Res. 2023 08 15; 83(16):2763-2774. Lundberg A, Zhang M, Aggarwal R, Li H, Zhang L, Foye A, Sjöström M, Chou J, Chang K, Moreno-Rodriguez T, Shrestha R, Baskin A, Zhu X, Weinstein AS, Younger N, Alumkal JJ, Beer TM, Chi KN, Evans CP, Gleave M, Lara PN, Reiter RE, Rettig MB, Witte ON, Wyatt AW, Feng FY, Small EJ, Quigley DA. PMID: 37289025; PMCID: PMC10425725.
      View in: PubMed   Mentions: 6     Fields:    
    4. Cardiovascular Effects of GnRH Antagonists Compared With Agonists in Prostate Cancer: A Systematic Review. JACC CardioOncol. 2023 Oct; 5(5):613-624. Nelson AJ, Lopes RD, Hong H, Hua K, Slovin S, Tan S, Nilsson J, Bhatt DL, Goodman SG, Evans CP, Clarke NW, Shore ND, Margel D, Klotz LH, Tombal B, Leong DP, Alexander JH, Higano CS. PMID: 37969642; PMCID: PMC10635880.
      View in: PubMed   Mentions: 1  
    5. The Impact of Positron Emission Tomography Imaging and Tumor Molecular Profiling on Risk Stratification, Treatment Choice, and Oncological Outcomes of Patients with Primary or Relapsed Prostate Cancer: An International Collaborative Review of the Existing Literature. Eur Urol Oncol. 2024 Feb; 7(1):27-43. Sood A, Kishan AU, Evans CP, Feng FY, Morgan TM, Murphy DG, Padhani AR, Pinto P, Van der Poel HG, Tilki D, Briganti A, Abdollah F. PMID: 37423774.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    6. The Metastatic Risk of Renal Cell Carcinoma by Primary Tumor Size and Subtype. Eur Urol Open Sci. 2023 Jun; 52:137-144. Monda SM, Lui HT, Pratsinis MA, Chandrasekar T, Evans CP, Dall'Era MA. PMID: 37284045; PMCID: PMC10240521.
      View in: PubMed   Mentions: 2  
    7. Androgen receptor blockade resistance with enzalutamide in prostate cancer results in immunosuppressive alterations in the tumor immune microenvironment. J Immunother Cancer. 2023 05; 11(5). Xu P, Yang JC, Chen B, Nip C, Van Dyke JE, Zhang X, Chen HW, Evans CP, Murphy WJ, Liu C. PMID: 37147019; PMCID: PMC10163595.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansAnimals
    8. Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022. Eur J Cancer. 2023 05; 185:178-215. Gillessen S, Bossi A, Davis ID, de Bono J, Fizazi K, James ND, Mottet N, Shore N, Small E, Smith M, Sweeney CJ, Tombal B, Antonarakis ES, Aparicio AM, Armstrong AJ, Attard G, Beer TM, Beltran H, Bjartell A, Blanchard P, Briganti A, Bristow RG, Bulbul M, Caffo O, Castellano D, Castro E, Cheng HH, Chi KN, Chowdhury S, Clarke CS, Clarke N, Daugaard G, De Santis M, Duran I, Eeles R, Efstathiou E, Efstathiou J, Ekeke ON, Evans CP, Fanti S, Feng FY, Fonteyne V, Fossati N, Frydenberg M, George D, Gleave M, Gravis G, Halabi S, Heinrich D, Herrmann K, Higano C, Hofman MS, Horvath LG, Hussain M, Jereczek-Fossa BA, Jones R, Kanesvaran R, Kellokumpu-Lehtinen PL, Khauli RB, Klotz L, Kramer G, Leibowitz R, Logothetis C, Mahal B, Maluf F, Mateo J, Matheson D, Mehra N, Merseburger A, Morgans AK, Morris MJ, Mrabti H, Mukherji D, Murphy DG, Murthy V, Nguyen PL, Oh WK, Ost P, O'Sullivan JM, Padhani AR, Pezaro CJ, Poon DMC, Pritchard CC, Rabah DM, Rathkopf D, Reiter RE, Rubin MA, Ryan CJ, Saad F, Sade JP, Sartor O, Scher HI, Sharifi N, Skoneczna I, Soule H, Spratt DE, Srinivas S, Sternberg CN, Steuber T, Suzuki H, Sydes MR, Taplin ME, Tilki D, Türkeri L, Turco F, Uemura H, Uemura H, Ürün Y, Vale CL, van Oort I, Vapiwala N, Walz J, Yamoah K, Ye D, Yu EY, Zapatero A, Zilli T, Omlin A. PMID: 37003085.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    9. Allosteric inhibition of HSP70 in collaboration with STUB1 augments enzalutamide efficacy in antiandrogen resistant prostate tumor and patient-derived models. Pharmacol Res. 2023 03; 189:106692. Xu P, Yang JC, Ning S, Chen B, Nip C, Wei Q, Liu L, Johnson OT, Gao AC, Gestwicki JE, Evans CP, Liu C. PMID: 36773708; PMCID: PMC10162009.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    10. Novel inhibition of AKR1C3 and androgen receptor axis by PTUPB synergizes enzalutamide treatment in advanced prostate cancer. Oncogene. 2023 02; 42(9):693-707. Yang JC, Xu P, Ning S, Wasielewski LJ, Adomat H, Hwang SH, Morisseau C, Gleave M, Corey E, Gao AC, Lara PN, Evans CP, Hammock BD, Liu C. PMID: 36596844; PMCID: PMC9975039.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    11. Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022. Eur Urol. 2023 03; 83(3):267-293. Gillessen S, Bossi A, Davis ID, de Bono J, Fizazi K, James ND, Mottet N, Shore N, Small E, Smith M, Sweeney C, Tombal B, Antonarakis ES, Aparicio AM, Armstrong AJ, Attard G, Beer TM, Beltran H, Bjartell A, Blanchard P, Briganti A, Bristow RG, Bulbul M, Caffo O, Castellano D, Castro E, Cheng HH, Chi KN, Chowdhury S, Clarke CS, Clarke N, Daugaard G, De Santis M, Duran I, Eeles R, Efstathiou E, Efstathiou J, Ngozi Ekeke O, Evans CP, Fanti S, Feng FY, Fonteyne V, Fossati N, Frydenberg M, George D, Gleave M, Gravis G, Halabi S, Heinrich D, Herrmann K, Higano C, Hofman MS, Horvath LG, Hussain M, Jereczek-Fossa BA, Jones R, Kanesvaran R, Kellokumpu-Lehtinen PL, Khauli RB, Klotz L, Kramer G, Leibowitz R, Logothetis CJ, Mahal BA, Maluf F, Mateo J, Matheson D, Mehra N, Merseburger A, Morgans AK, Morris MJ, Mrabti H, Mukherji D, Murphy DG, Murthy V, Nguyen PL, Oh WK, Ost P, O'Sullivan JM, Padhani AR, Pezaro C, Poon DMC, Pritchard CC, Rabah DM, Rathkopf D, Reiter RE, Rubin MA, Ryan CJ, Saad F, Pablo Sade J, Sartor OA, Scher HI, Sharifi N, Skoneczna I, Soule H, Spratt DE, Srinivas S, Sternberg CN, Steuber T, Suzuki H, Sydes MR, Taplin ME, Tilki D, Türkeri L, Turco F, Uemura H, Uemura H, Ürün Y, Vale CL, van Oort I, Vapiwala N, Walz J, Yamoah K, Ye D, Yu EY, Zapatero A, Zilli T, Omlin A. PMID: 36494221; PMCID: PMC7614721.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    12. The 5-Hydroxymethylcytosine Landscape of Prostate Cancer. Cancer Res. 2022 11 02; 82(21):3888-3902. Sjöström M, Zhao SG, Levy S, Zhang M, Ning Y, Shrestha R, Lundberg A, Herberts C, Foye A, Aggarwal R, Hua JT, Li H, Bergamaschi A, Maurice-Dror C, Maheshwari A, Chen S, Ng SWS, Ye W, Petricca J, Fraser M, Chesner L, Perry MD, Moreno-Rodriguez T, Chen WS, Alumkal JJ, Chou J, Morgans AK, Beer TM, Thomas GV, Gleave M, Lloyd P, Phillips T, McCarthy E, Haffner MC, Zoubeidi A, Annala M, Reiter RE, Rettig MB, Witte ON, Fong L, Bose R, Huang FW, Luo J, Bjartell A, Lang JM, Mahajan NP, Lara PN, Evans CP, Tran PT, Posadas EM, He C, Cui XL, Huang J, Zwart W, Gilbert LA, Maher CA, Boutros PC, Chi KN, Ashworth A, Small EJ, He HH, Wyatt AW, Quigley DA, Feng FY. PMID: 36251389; PMCID: PMC9627125.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    13. Bioengineered BERA-Wnt5a siRNA Targeting Wnt5a/FZD2 Signaling Suppresses Advanced Prostate Cancer Tumor Growth and Enhances Enzalutamide Treatment. Mol Cancer Ther. 2022 10 07; 21(10):1594-1607. Ning S, Liu C, Lou W, Yang JC, Lombard AP, D'Abronzo LS, Batra N, Yu AM, Leslie AR, Sharifi M, Evans CP, Gao AC. PMID: 35930737; PMCID: PMC9547958.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    14. Activation of neural lineage networks and ARHGEF2 in enzalutamide-resistant and neuroendocrine prostate cancer and association with patient outcomes. Commun Med (Lond). 2022; 2:118. Ning S, Zhao J, Lombard AP, D'Abronzo LS, Leslie AR, Sharifi M, Lou W, Liu C, Yang JC, Evans CP, Corey E, Chen HW, Yu A, Ghosh PM, Gao AC. PMID: 36159187; PMCID: PMC9492734.
      View in: PubMed   Mentions: 2  
    15. Transcriptional profiling of matched patient biopsies clarifies molecular determinants of enzalutamide-induced lineage plasticity. Nat Commun. 2022 09 15; 13(1):5345. Westbrook TC, Guan X, Rodansky E, Flores D, Liu CJ, Udager AM, Patel RA, Haffner MC, Hu YM, Sun D, Beer TM, Foye A, Aggarwal R, Quigley DA, Youngren JF, Ryan CJ, Gleave M, Wang Y, Huang J, Coleman I, Morrissey C, Nelson PS, Evans CP, Lara P, Reiter RE, Witte O, Rettig M, Wong CK, Weinstein AS, Uzunangelov V, Stuart JM, Thomas GV, Feng FY, Small EJ, Yates JA, Xia Z, Alumkal JJ. PMID: 36109521; PMCID: PMC9477876.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    16. The Immunotherapy and Immunosuppressive Signaling in Therapy-Resistant Prostate Cancer. Biomedicines. 2022 Jul 22; 10(8). Xu P, Wasielewski LJ, Yang JC, Cai D, Evans CP, Murphy WJ, Liu C. PMID: 35892678; PMCID: PMC9394279.
      View in: PubMed   Mentions: 7  
    17. Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021. Eur Urol. 2022 07; 82(1):115-141. Gillessen S, Armstrong A, Attard G, Beer TM, Beltran H, Bjartell A, Bossi A, Briganti A, Bristow RG, Bulbul M, Caffo O, Chi KN, Clarke CS, Clarke N, Davis ID, de Bono JS, Duran I, Eeles R, Efstathiou E, Efstathiou J, Ekeke ON, Evans CP, Fanti S, Feng FY, Fizazi K, Frydenberg M, George D, Gleave M, Halabi S, Heinrich D, Higano C, Hofman MS, Hussain M, James N, Jones R, Kanesvaran R, Khauli RB, Klotz L, Leibowitz R, Logothetis C, Maluf F, Millman R, Morgans AK, Morris MJ, Mottet N, Mrabti H, Murphy DG, Murthy V, Oh WK, Ost P, O'Sullivan JM, Padhani AR, Parker C, Poon DMC, Pritchard CC, Rabah DM, Rathkopf D, Reiter RE, Rubin M, Ryan CJ, Saad F, Sade JP, Sartor O, Scher HI, Shore N, Skoneczna I, Small E, Smith M, Soule H, Spratt DE, Sternberg CN, Suzuki H, Sweeney C, Sydes MR, Taplin ME, Tilki D, Tombal B, Türkeri L, Uemura H, Uemura H, van Oort I, Yamoah K, Ye D, Zapatero A, Omlin A. PMID: 35450732.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    18. Corrigendum to "What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021" [Eur Urol 82(1):6-11]. Eur Urol. 2022 Jul; 82(1):e18-e19. Turco F, Armstrong A, Attard G, Beer TM, Beltran H, Bjartell A, Bossi A, Briganti A, Bristow RG, Bulbul M, Caffo O, Chi KN, Clarke C, Clarke N, Davis ID, de Bono J, Duran I, Eeles R, Efstathiou E, Efstathiou J, Evans CP, Fanti S, Feng FY, Fizazi K, Frydenberg M, George D, Gleave M, Halabi S, Heinrich D, Higano C, Hofman MS, Hussain M, James N, Jones R, Kanesvaran R, Khauli RB, Klotz L, Leibowitz R, Logothetis C, Maluf F, Millman R, Morgans AK, Morris MJ, Mottet N, Mrabti H, Murphy DG, Murthy V, Oh WK, Ekeke ON, Ost P, O'Sullivan JM, Padhani AR, Parker C, Poon DMC, Pritchard CC, Rabah DM, Rathkopf D, Reiter RE, Rubin M, Ryan CJ, Saad F, Sade JP, Sartor O, Scher HI, Shore N, Skoneczna I, Small E, Smith M, Soule H, Spratt D, Sternberg CN, Suzuki H, Sweeney C, Sydes M, Taplin ME, Tilki D, Tombal B, Türkeri L, Uemura H, Uemura H, van Oort I, Yamoah K, Ye D, Zapatero A, Gillessen S, Omlin A. PMID: 35440417; PMCID: PMC9012951.
      View in: PubMed   Mentions:    Fields:    
    19. Olaparib-Induced Senescence Is Bypassed through G2-M Checkpoint Override in Olaparib-Resistant Prostate Cancer. Mol Cancer Ther. 2022 04 01; 21(4):677-685. Lombard AP, Armstrong CM, D'Abronzo LS, Ning S, Leslie AR, Sharifi M, Lou W, Evans CP, Dall'Era M, Chen HW, Chen X, Gao AC. PMID: 35086956; PMCID: PMC8983570.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    20. What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021. Eur Urol. 2022 07; 82(1):6-11. Turco F, Armstrong A, Attard G, Beer TM, Beltran H, Bjartell A, Bossi A, Briganti A, Bristow RG, Bulbul M, Caffo O, Chi KN, Clarke C, Clarke N, Davis ID, de Bono J, Duran I, Eeles R, Efstathiou E, Efstathiou J, Evans CP, Fanti S, Feng FY, Fizazi K, Frydenberg M, George D, Gleave M, Halabi S, Heinrich D, Higano C, Hofman MS, Hussain M, James N, Jones R, Kanesvaran R, Khauli RB, Klotz L, Leibowitz R, Logothetis C, Maluf F, Millman R, Morgans AK, Morris MJ, Mottet N, Mrabti H, Murphy DG, Murthy V, Oh WK, Ekeke Onyeanunam N, Ost P, O'Sullivan JM, Padhani AR, Parker C, Poon DMC, Pritchard CC, Rabah DM, Rathkopf D, Reiter RE, Rubin M, Ryan CJ, Saad F, Pablo Sade J, Sartor O, Scher HI, Shore N, Skoneczna I, Small E, Smith M, Soule H, Spratt D, Sternberg CN, Suzuki H, Sweeney C, Sydes M, Taplin ME, Tilki D, Tombal B, Türkeri L, Uemura H, Uemura H, van Oort I, Yamoah K, Ye D, Zapatero A, Gillessen S, Omlin A. PMID: 35393158; PMCID: PMC8849852.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansPHPublic Health
    21. Genetic Factors Associated with Prostate Cancer Conversion from Active Surveillance to Treatment. HGG Adv. 2022 Jan 13; 3(1). Jiang Y, Meyers TJ, Emeka AA, Cooley LF, Cooper PR, Lancki N, Helenowski I, Kachuri L, Lin DW, Stanford JL, Newcomb LF, Kolb S, Finelli A, Fleshner NE, Komisarenko M, Eastham JA, Ehdaie B, Benfante N, Logothetis CJ, Gregg JR, Perez CA, Garza S, Kim J, Marks LS, Delfin M, Barsa D, Vesprini D, Klotz LH, Loblaw A, Mamedov A, Goldenberg SL, Higano CS, Spillane M, Wu E, Carter HB, Pavlovich CP, Mamawala M, Landis T, Carroll PR, Chan JM, Cooperberg MR, Cowan JE, Morgan TM, Siddiqui J, Martin R, Klein EA, Brittain K, Gotwald P, Barocas DA, Dallmer JR, Gordetsky JB, Steele P, Kundu SD, Stockdale J, Roobol MJ, Venderbos LDF, Sanda MG, Arnold R, Patil D, Evans CP, Dall'Era MA, Vij A, Costello AJ, Chow K, Corcoran NM, Rais-Bahrami S, Phares C, Scherr DS, Flynn T, Karnes RJ, Koch M, Dhondt CR, Nelson JB, McBride D, Cookson MS, Stratton KL, Farriester S, Hemken E, Stadler WM, Pera T, Banionyte D, Bianco FJ, Lopez IH, Loeb S, Taneja SS, Byrne N, Amling CL, Martinez A, Boileau L, Gaylis FD, Petkewicz J, Kirwen N, Helfand BT, Xu J, Scholtens DM, Catalona WJ, Witte JS. PMID: 34993496; PMCID: PMC8725988.
      View in: PubMed   Mentions: 10  
    22. Prognosis Associated With Luminal and Basal Subtypes of Metastatic Prostate Cancer. JAMA Oncol. 2021 Nov 01; 7(11):1644-1652. Aggarwal R, Rydzewski NR, Zhang L, Foye A, Kim W, Helzer KT, Bakhtiar H, Chang SL, Perry MD, Gleave M, Reiter RE, Huang J, Evans CP, Alumkal JJ, Lang JM, Yu M, Quigley DA, Sjöström M, Small EJ, Feng FY, Zhao SG. PMID: 34554200; PMCID: PMC8461554.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    23. Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial. Circulation. 2021 10 19; 144(16):1295-1307. Lopes RD, Higano CS, Slovin SF, Nelson AJ, Bigelow R, Sørensen PS, Melloni C, Goodman SG, Evans CP, Nilsson J, Bhatt DL, Clarke NW, Olesen TK, Doyle-Olsen BT, Kristensen H, Arney L, Roe MT, Alexander JH, PRONOUNCE Study Investigators. PMID: 34459214; PMCID: PMC9004319.
      View in: PubMed   Mentions: 40     Fields:    Translation:Humans
    24. Activation of the ABCB1 Amplicon in Docetaxel- and Cabazitaxel-Resistant Prostate Cancer Cells. Mol Cancer Ther. 2021 10; 20(10):2061-2070. Lombard AP, Lou W, Armstrong CM, D'Abronzo LS, Ning S, Evans CP, Gao AC. PMID: 34326198; PMCID: PMC8492550.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    25. ARVib suppresses growth of advanced prostate cancer via inhibition of androgen receptor signaling. Oncogene. 2021 09; 40(35):5379-5392. Liu C, Armstrong CM, Ning S, Yang JC, Lou W, Lombard AP, Zhao J, Wu CY, Yu A, Evans CP, Tepper CG, Li PK, Gao AC. PMID: 34272475; PMCID: PMC8413131.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCells
    26. Re: Regional Adoption of Commercial Gene Expression Testing for Prostate Cancer. Eur Urol. 2021 10; 80(4):519-520. Tilki D, Evans CP. PMID: 34119382.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    27. Comparison of Joint and Landmark Modeling for Predicting Cancer Progression in Men With Castration-Resistant Prostate Cancer: A Secondary Post Hoc Analysis of the PREVAIL Randomized Clinical Trial. JAMA Netw Open. 2021 06 01; 4(6):e2112426. Finelli A, Beer TM, Chowdhury S, Evans CP, Fizazi K, Higano CS, Kim J, Martin L, Saad F, Saarela O. PMID: 34129025; PMCID: PMC8207237.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    28. Targeting Feedforward Loops Formed by Nuclear Receptor RORγ and Kinase PBK in mCRPC with Hyperactive AR Signaling. Cancers (Basel). 2021 Apr 01; 13(7). Zhang X, Huang Z, Wang J, Ma Z, Yang J, Corey E, Evans CP, Yu AM, Chen HW. PMID: 33916325; PMCID: PMC8036795.
      View in: PubMed   Mentions: 5  
    29. Recent Advances in Epigenetic Biomarkers and Epigenetic Targeting in Prostate Cancer. Eur Urol. 2021 07; 80(1):71-81. Kumaraswamy A, Welker Leng KR, Westbrook TC, Yates JA, Zhao SG, Evans CP, Feng FY, Morgan TM, Alumkal JJ. PMID: 33785255; PMCID: PMC8547521.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCells
    30. Phase Ib trial of reformulated niclosamide with abiraterone/prednisone in men with castration-resistant prostate cancer. Sci Rep. 2021 03 18; 11(1):6377. Parikh M, Liu C, Wu CY, Evans CP, Dall'Era M, Robles D, Lara PN, Agarwal N, Gao AC, Pan CX. PMID: 33737681; PMCID: PMC7973745.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansCTClinical Trials
    31. Impact of Pelvic Lymph Node Dissection and Its Extent on Perioperative Morbidity in Patients Undergoing Radical Prostatectomy for Prostate Cancer: A Comprehensive Systematic Review and Meta-analysis. Eur Urol Oncol. 2021 04; 4(2):134-149. Cacciamani GE, Maas M, Nassiri N, Ortega D, Gill K, Dell'Oglio P, Thalmann GN, Heidenreich A, Eastham JA, Evans CP, Karnes RJ, De Castro Abreu AL, Briganti A, Artibani W, Gill I, Montorsi F. PMID: 33745687.
      View in: PubMed   Mentions: 27     Fields:    Translation:Humans
    32. Assessment of Postprostatectomy Radiotherapy as Adjuvant or Salvage Therapy in Patients With Prostate Cancer: A Systematic Review. JAMA Oncol. 2020 Nov 01; 6(11):1793-1800. Sachdev S, Carroll P, Sandler H, Nguyen PL, Wafford E, Auffenberg G, Schaeffer E, Roach M, Evans CP, Hussain M. PMID: 32852528.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    33. Newly Diagnosed High-Risk Prostate Cancer in an Era of Rapidly Evolving New Imaging: How Do We Treat? J Clin Oncol. 2021 01 01; 39(1):13-16. Hussain M, Lin D, Saad F, Vapiwala N, Chapin BF, Sandler H, Evans CP, Carducci MA, Sachdev S. PMID: 33048621.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    34. Autoantibody Landscape in Patients with Advanced Prostate Cancer. Clin Cancer Res. 2020 12 01; 26(23):6204-6214. Chen WS, Haynes WA, Waitz R, Kamath K, Vega-Crespo A, Shrestha R, Zhang M, Foye A, Baselga Carretero I, Perez Garcilazo I, Zhang M, Zhao SG, Sjöström M, Quigley DA, Chou J, Beer TM, Rettig M, Gleave M, Evans CP, Lara P, Chi KN, Reiter RE, Alumkal JJ, Ashworth A, Aggarwal R, Small EJ, Daugherty PS, Ribas A, Oh DY, Shon JC, Feng FY. PMID: 32967941; PMCID: PMC7710628.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    35. Steroid Sulfatase Stimulates Intracrine Androgen Synthesis and is a Therapeutic Target for Advanced Prostate Cancer. Clin Cancer Res. 2020 11 15; 26(22):6064-6074. Armstrong CM, Liu C, Liu L, Yang JC, Lou W, Zhao R, Ning S, Lombard AP, Zhao J, D'Abronzo LS, Evans CP, Li PK, Gao AC. PMID: 32928794; PMCID: PMC7669645.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCells
    36. Copy Number Loss of 17q22 Is Associated with Enzalutamide Resistance and Poor Prognosis in Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2020 09 01; 26(17):4616-4624. Guan X, Sun D, Lu E, Urrutia JA, Reiter RE, Rettig M, Evans CP, Lara P, Gleave M, Beer TM, Thomas GV, Huang J, Aggarwal RR, Quigley DA, Foye A, Chen WS, Youngren J, Weinstein AS, Stuart JM, Feng FY, Small EJ, Xia Z, Alumkal JJ. PMID: 32727885; PMCID: PMC7484240.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    37. Cancer and Leukemia Group B 90203 (Alliance): Radical Prostatectomy With or Without Neoadjuvant Chemohormonal Therapy in Localized, High-Risk Prostate Cancer. J Clin Oncol. 2020 09 10; 38(26):3042-3050. Eastham JA, Heller G, Halabi S, Monk JP, Beltran H, Gleave M, Evans CP, Clinton SK, Szmulewitz RZ, Coleman J, Hillman DW, Watt CR, George S, Sanda MG, Hahn OM, Taplin ME, Parsons JK, Mohler JL, Small EJ, Morris MJ. PMID: 32706639; PMCID: PMC7479762.
      View in: PubMed   Mentions: 32     Fields:    Translation:Humans
    38. The DNA methylation landscape of advanced prostate cancer. Nat Genet. 2020 08; 52(8):778-789. Zhao SG, Chen WS, Li H, Foye A, Zhang M, Sjöström M, Aggarwal R, Playdle D, Liao A, Alumkal JJ, Das R, Chou J, Hua JT, Barnard TJ, Bailey AM, Chow ED, Perry MD, Dang HX, Yang R, Moussavi-Baygi R, Zhang L, Alshalalfa M, Laura Chang S, Houlahan KE, Shiah YJ, Beer TM, Thomas G, Chi KN, Gleave M, Zoubeidi A, Reiter RE, Rettig MB, Witte O, Yvonne Kim M, Fong L, Spratt DE, Morgan TM, Bose R, Huang FW, Li H, Chesner L, Shenoy T, Goodarzi H, Asangani IA, Sandhu S, Lang JM, Mahajan NP, Lara PN, Evans CP, Febbo P, Batzoglou S, Knudsen KE, He HH, Huang J, Zwart W, Costello JF, Luo J, Tomlins SA, Wyatt AW, Dehm SM, Ashworth A, Gilbert LA, Boutros PC, Farh K, Chinnaiyan AM, Maher CA, Small EJ, Quigley DA, Feng FY. PMID: 32661416; PMCID: PMC7454228.
      View in: PubMed   Mentions: 122     Fields:    Translation:HumansCells
    39. Cross-Resistance Among Next-Generation Antiandrogen Drugs Through the AKR1C3/AR-V7 Axis in Advanced Prostate Cancer. Mol Cancer Ther. 2020 08; 19(8):1708-1718. Zhao J, Ning S, Lou W, Yang JC, Armstrong CM, Lombard AP, D'Abronzo LS, Evans CP, Gao AC, Liu C. PMID: 32430485; PMCID: PMC8855880.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCells
    40. Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistance. Proc Natl Acad Sci U S A. 2020 06 02; 117(22):12315-12323. Alumkal JJ, Sun D, Lu E, Beer TM, Thomas GV, Latour E, Aggarwal R, Cetnar J, Ryan CJ, Tabatabaei S, Bailey S, Turina CB, Quigley DA, Guan X, Foye A, Youngren JF, Urrutia J, Huang J, Weinstein AS, Friedl V, Rettig M, Reiter RE, Spratt DE, Gleave M, Evans CP, Stuart JM, Chen Y, Feng FY, Small EJ, Witte ON, Xia Z. PMID: 32424106; PMCID: PMC7275746.
      View in: PubMed   Mentions: 59     Fields:    Translation:HumansCTClinical Trials
    41. Cardiovascular Safety of Degarelix Versus Leuprolide for Advanced Prostate Cancer: The PRONOUNCE Trial Study Design. JACC CardioOncol. 2020 Mar; 2(1):70-81. Melloni C, Slovin SF, Blemings A, Goodman SG, Evans CP, Nilsson J, Bhatt DL, Zubovskiy K, Olesen TK, Dugi K, Clarke NW, Higano CS, Roe MT, PRONOUNCE Investigators. PMID: 34396210; PMCID: PMC8352040.
      View in: PubMed   Mentions: 23  
    42. Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. Eur Urol. 2020 04; 77(4):508-547. Gillessen S, Attard G, Beer TM, Beltran H, Bjartell A, Bossi A, Briganti A, Bristow RG, Chi KN, Clarke N, Davis ID, de Bono J, Drake CG, Duran I, Eeles R, Efstathiou E, Evans CP, Fanti S, Feng FY, Fizazi K, Frydenberg M, Gleave M, Halabi S, Heidenreich A, Heinrich D, Higano CTS, Hofman MS, Hussain M, James N, Kanesvaran R, Kantoff P, Khauli RB, Leibowitz R, Logothetis C, Maluf F, Millman R, Morgans AK, Morris MJ, Mottet N, Mrabti H, Murphy DG, Murthy V, Oh WK, Ost P, O'Sullivan JM, Padhani AR, Parker C, Poon DMC, Pritchard CC, Reiter RE, Roach M, Rubin M, Ryan CJ, Saad F, Sade JP, Sartor O, Scher HI, Shore N, Small E, Smith M, Soule H, Sternberg CN, Steuber T, Suzuki H, Sweeney C, Sydes MR, Taplin ME, Tombal B, Türkeri L, van Oort I, Zapatero A, Omlin A. PMID: 32001144.
      View in: PubMed   Mentions: 139     Fields:    Translation:Humans
    43. Framing Pragmatic Strategies to Reduce Mortality From Bladder Cancer: An Endorsement From the Society of Urologic Oncology. J Clin Oncol. 2020 06 01; 38(16):1760-1762. de Vere White R, Lara PN, Black PC, Evans CP, Dall'Era M. PMID: 31951493.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    44. A Case Series of Preoperative Endovascular Stenting in Patients Undergoing Postchemotherapy Resection of Complex Oncologic Masses. Eur Urol Oncol. 2020 02; 3(1):1-6. Amend G, Palvolgyi R, Rodriguez VM, Bold RJ, Evans CP. PMID: 31892469.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    45. Germline polymorphisms associated with impaired survival outcomes and somatic tumor alterations in advanced prostate cancer. Prostate Cancer Prostatic Dis. 2020 06; 23(2):316-323. Chen WS, Feng EL, Aggarwal R, Foye A, Beer TM, Alumkal JJ, Gleave M, Chi KN, Reiter RE, Rettig MB, Evans CP, Small EJ, Sharifi N, Zhao SG. PMID: 31745256; PMCID: PMC7529063.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    46. Therapeutic Targeting of MDR1 Expression by RORγ Antagonists Resensitizes Cross-Resistant CRPC to Taxane via Coordinated Induction of Cell Death Programs. Mol Cancer Ther. 2020 02; 19(2):364-374. Wang Y, Huang Z, Chen CZ, Liu C, Evans CP, Gao AC, Zhou F, Chen HW. PMID: 31712394.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansAnimalsCells
    47. Utility of Intraprocedural Contrast-Enhanced CT in Ablation of Renal Masses. AJR Am J Roentgenol. 2020 01; 214(1):122-128. Grewal A, Khera SS, McGahan JP, Wilson M, Loehfelm TW, Dall'Era MA, Evans CP. PMID: 31532258; PMCID: PMC7552890.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    48. Wntless promotes cellular viability and resistance to enzalutamide in castration-resistant prostate cancer cells. Am J Clin Exp Urol. 2019; 7(4):203-214. Lombard AP, Liu C, Armstrong CM, D'Abronzo LS, Lou W, Evans CP, Gao AC. PMID: 31511827; PMCID: PMC6734040.
      View in: PubMed   Mentions: 10  
    49. GnRH Antagonists Have Direct Inhibitory Effects On Castration-Resistant Prostate Cancer Via Intracrine Androgen and AR-V7 Expression. Mol Cancer Ther. 2019 10; 18(10):1811-1821. Cucchiara V, Yang JC, Liu C, Adomat HH, Tomlinson Guns ES, Gleave ME, Gao AC, Evans CP. PMID: 31341032.
      View in: PubMed   Mentions: 5     Fields:    Translation:AnimalsCells
    50. AKR1C3 Promotes AR-V7 Protein Stabilization and Confers Resistance to AR-Targeted Therapies in Advanced Prostate Cancer. Mol Cancer Ther. 2019 10; 18(10):1875-1886. Liu C, Yang JC, Armstrong CM, Lou W, Liu L, Qiu X, Zou B, Lombard AP, D'Abronzo LS, Evans CP, Gao AC. PMID: 31308078; PMCID: PMC6995728.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansAnimalsCells
    51. Association of an organ transplant-based approach with a dramatic reduction in postoperative complications following radical nephrectomy and tumor thrombectomy in renal cell carcinoma. Eur J Surg Oncol. 2019 Oct; 45(10):1983-1992. González J, Gaynor JJ, Martínez-Salamanca JI, Capitanio U, Tilki D, Carballido JA, Chantada V, Daneshmand S, Evans CP, Gasch C, Gontero P, Haferkamp A, Huang WC, Espinós EL, Master VA, McKiernan JM, Montorsi F, Pahernik S, Palou J, Pruthi RS, Rodriguez-Faba O, Russo P, Scherr DS, Shariat SF, Spahn M, Terrone C, Vera-Donoso C, Zigeuner R, Hohenfellner M, Libertino JA, Ciancio G. PMID: 31155470; PMCID: PMC8404534.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    52. Overexpressed ABCB1 Induces Olaparib-Taxane Cross-Resistance in Advanced Prostate Cancer. Transl Oncol. 2019 Jul; 12(7):871-878. Lombard AP, Liu C, Armstrong CM, D'Abronzo LS, Lou W, Chen H, Dall'Era M, Ghosh PM, Evans CP, Gao AC. PMID: 31075528; PMCID: PMC6510951.
      View in: PubMed   Mentions: 9  
    53. Genomic Drivers of Poor Prognosis and Enzalutamide Resistance in Metastatic Castration-resistant Prostate Cancer. Eur Urol. 2019 11; 76(5):562-571. Chen WS, Aggarwal R, Zhang L, Zhao SG, Thomas GV, Beer TM, Quigley DA, Foye A, Playdle D, Huang J, Lloyd P, Lu E, Sun D, Guan X, Rettig M, Gleave M, Evans CP, Youngren J, True L, Lara P, Kothari V, Xia Z, Chi KN, Reiter RE, Maher CA, Feng FY, Small EJ, Alumkal JJ, West Coast Prostate Cancer Dream Team. PMID: 30928160; PMCID: PMC6764911.
      View in: PubMed   Mentions: 61     Fields:    Translation:Humans
    54. Whole-Genome and Transcriptional Analysis of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer Demonstrates Intraclass Heterogeneity. Mol Cancer Res. 2019 06; 17(6):1235-1240. Aggarwal RR, Quigley DA, Huang J, Zhang L, Beer TM, Rettig MB, Reiter RE, Gleave ME, Thomas GV, Foye A, Playdle D, Lloyd P, Chi KN, Evans CP, Lara PN, Feng FY, Alumkal JJ, Small EJ. PMID: 30918106; PMCID: PMC6548614.
      View in: PubMed   Mentions: 34     Fields:    Translation:HumansCells
    55. MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer. Prostate Cancer Prostatic Dis. 2019 12; 22(4):531-538. Nickols NG, Nazarian R, Zhao SG, Tan V, Uzunangelov V, Xia Z, Baertsch R, Neeman E, Gao AC, Thomas GV, Howard L, De Hoedt AM, Stuart J, Goldstein T, Chi K, Gleave ME, Graff JN, Beer TM, Drake JM, Evans CP, Aggarwal R, Foye A, Feng FY, Small EJ, Aronson WJ, Freedland SJ, Witte ON, Huang J, Alumkal JJ, Reiter RE, Rettig MB. PMID: 30804427; PMCID: PMC6853839.
      View in: PubMed   Mentions: 43     Fields:    Translation:HumansCells
    56. Cytoreductive Nephrectomy in Metastatic Renal Cell Cancer: Not All That It's Cut Out to Be. JAMA Oncol. 2019 02 01; 5(2):171-172. Lara PN, Evans CP. PMID: 30543365.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    57. Re: Radiotherapy to the Primary Tumour for Newly Diagnosed, Metastatic Prostate Cancer (STAMPEDE): A Randomised Controlled Phase 3 Trial. Eur Urol. 2019 03; 75(3):535-536. Tilki D, Evans CP. PMID: 30466892.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    58. Proteostasis by STUB1/HSP70 complex controls sensitivity to androgen receptor targeted therapy in advanced prostate cancer. Nat Commun. 2018 11 16; 9(1):4700. Liu C, Lou W, Yang JC, Liu L, Armstrong CM, Lombard AP, Zhao R, Noel ODV, Tepper CG, Chen HW, Dall'Era M, Evans CP, Gao AC. PMID: 30446660; PMCID: PMC6240084.
      View in: PubMed   Mentions: 44     Fields:    Translation:HumansAnimalsCells
    59. Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. Cell. 2018 10 18; 175(3):889. Quigley DA, Dang HX, Zhao SG, Lloyd P, Aggarwal R, Alumkal JJ, Foye A, Kothari V, Perry MD, Bailey AM, Playdle D, Barnard TJ, Zhang L, Zhang J, Youngren JF, Cieslik MP, Parolia A, Beer TM, Thomas G, Chi KN, Gleave M, Lack NA, Zoubeidi A, Reiter RE, Rettig MB, Witte O, Ryan CJ, Fong L, Kim W, Friedlander T, Chou J, Li H, Das R, Li H, Moussavi-Baygi R, Goodarzi H, Gilbert LA, Lara PN, Evans CP, Goldstein TC, Stuart JM, Tomlins SA, Spratt DE, Cheetham RK, Cheng DT, Farh K, Gehring JS, Hakenberg J, Liao A, Febbo PG, Shon J, Sickler B, Batzoglou S, Knudsen KE, He HH, Huang J, Wyatt AW, Dehm SM, Ashworth A, Chinnaiyan AM, Maher CA, Small EJ, Feng FY. PMID: 30340047.
      View in: PubMed   Mentions: 64     Fields:    
    60. Non-metastatic castration resistant prostate cancer: a review of current and emerging medical therapies. Prostate Cancer Prostatic Dis. 2019 03; 22(1):16-23. Alpajaro SIR, Harris JAK, Evans CP. PMID: 30115959.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansAnimals
    61. KDM8/JMJD5 as a dual coactivator of AR and PKM2 integrates AR/EZH2 network and tumor metabolism in CRPC. Oncogene. 2019 01; 38(1):17-32. Wang HJ, Pochampalli M, Wang LY, Zou JX, Li PS, Hsu SC, Wang BJ, Huang SH, Yang P, Yang JC, Chu CY, Hsieh CL, Sung SY, Li CF, Tepper CG, Ann DK, Gao AC, Evans CP, Izumiya Y, Chuu CP, Wang WC, Chen HW, Kung HJ. PMID: 30072740; PMCID: PMC6755995.
      View in: PubMed   Mentions: 53     Fields:    Translation:HumansAnimalsCells
    62. Retroperitoneal extramedullary hematopoietic pseudotumor in ataxia-telangiectasia. Rare Tumors. 2018; 10:2036361318789724. Judge SJ, Plescia TA, Bateni CP, Darrow MA, Evans CP, Canter RJ. PMID: 30046399; PMCID: PMC6056779.
      View in: PubMed   Mentions: 1  
    63. Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. Cell. 2018 07 26; 174(3):758-769.e9. Quigley DA, Dang HX, Zhao SG, Lloyd P, Aggarwal R, Alumkal JJ, Foye A, Kothari V, Perry MD, Bailey AM, Playdle D, Barnard TJ, Zhang L, Zhang J, Youngren JF, Cieslik MP, Parolia A, Beer TM, Thomas G, Chi KN, Gleave M, Lack NA, Zoubeidi A, Reiter RE, Rettig MB, Witte O, Ryan CJ, Fong L, Kim W, Friedlander T, Chou J, Li H, Das R, Li H, Moussavi-Baygi R, Goodarzi H, Gilbert LA, Lara PN, Evans CP, Goldstein TC, Stuart JM, Tomlins SA, Spratt DE, Cheetham RK, Cheng DT, Farh K, Gehring JS, Hakenberg J, Liao A, Febbo PG, Shon J, Sickler B, Batzoglou S, Knudsen KE, He HH, Huang J, Wyatt AW, Dehm SM, Ashworth A, Chinnaiyan AM, Maher CA, Small EJ, Feng FY. PMID: 30033370; PMCID: PMC6425931.
      View in: PubMed   Mentions: 263     Fields:    Translation:HumansCells
    64. Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study. J Clin Oncol. 2018 08 20; 36(24):2492-2503. Aggarwal R, Huang J, Alumkal JJ, Zhang L, Feng FY, Thomas GV, Weinstein AS, Friedl V, Zhang C, Witte ON, Lloyd P, Gleave M, Evans CP, Youngren J, Beer TM, Rettig M, Wong CK, True L, Foye A, Playdle D, Ryan CJ, Lara P, Chi KN, Uzunangelov V, Sokolov A, Newton Y, Beltran H, Demichelis F, Rubin MA, Stuart JM, Small EJ. PMID: 29985747; PMCID: PMC6366813.
      View in: PubMed   Mentions: 303     Fields:    Translation:HumansCellsCTClinical Trials
    65. Intra versus Inter Cross-resistance Determines Treatment Sequence between Taxane and AR-Targeting Therapies in Advanced Prostate Cancer. Mol Cancer Ther. 2018 10; 17(10):2197-2205. Lombard AP, Liu L, Cucchiara V, Liu C, Armstrong CM, Zhao R, Yang JC, Lou W, Evans CP, Gao AC. PMID: 29891490; PMCID: PMC6168406.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCells
    66. Effect of Intravesical Instillation of Gemcitabine vs Saline Immediately Following Resection of Suspected Low-Grade Non-Muscle-Invasive Bladder Cancer on Tumor Recurrence: SWOG S0337 Randomized Clinical Trial. JAMA. 2018 05 08; 319(18):1880-1888. Messing EM, Tangen CM, Lerner SP, Sahasrabudhe DM, Koppie TM, Wood DP, Mack PC, Svatek RS, Evans CP, Hafez KS, Culkin DJ, Brand TC, Karsh LI, Holzbeierlein JM, Wilson SS, Wu G, Plets M, Vogelzang NJ, Thompson IM. PMID: 29801011; PMCID: PMC6583489.
      View in: PubMed   Mentions: 60     Fields:    Translation:HumansCTClinical Trials
    67. Development of a stress response therapy targeting aggressive prostate cancer. Sci Transl Med. 2018 05 02; 10(439). Nguyen HG, Conn CS, Kye Y, Xue L, Forester CM, Cowan JE, Hsieh AC, Cunningham JT, Truillet C, Tameire F, Evans MJ, Evans CP, Yang JC, Hann B, Koumenis C, Walter P, Carroll PR, Ruggero D. PMID: 29720449; PMCID: PMC6045425.
      View in: PubMed   Mentions: 79     Fields:    Translation:HumansAnimalsCells
    68. Local treatment for metastatic prostate cancer: A systematic review. Int J Urol. 2018 05; 25(5):390-403. Tilki D, Pompe RS, Bandini M, Marchioni M, Kretschmer A, Tian Z, Karakiewicz PI, Evans CP. PMID: 29572963.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    69. Naming disease states for clinical utility in prostate cancer: a rose by any other name might not smell as sweet. Ann Oncol. 2018 01 01; 29(1):23-25. Armstrong AJ, Antonarakis ES, Taplin ME, Kelly WK, Beltran H, Fizazi K, Dahut WL, Shore N, Slovin S, George D, Carducci MA, Corn P, Danila D, Dreicer R, Heath E, Rathkopf D, Liu G, Nanus D, Stein M, Smith MR, Sternberg C, Wilding G, Nelson PS, Halabi S, Kantoff P, Clarke NW, Evans CP, Heidenreich A, Mottet N, Gleave M, Morris MJ, Scher HI. PMID: 29088323; PMCID: PMC6248721.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    70. Bipolar androgen therapy: an intriguing paradox. Lancet Oncol. 2018 01; 19(1):8-10. Evans CP. PMID: 29248235.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    71. Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer. J Natl Cancer Inst. 2017 Dec 01; 109(12). Wyatt AW, Annala M, Aggarwal R, Beja K, Feng F, Youngren J, Foye A, Lloyd P, Nykter M, Beer TM, Alumkal JJ, Thomas GV, Reiter RE, Rettig MB, Evans CP, Gao AC, Chi KN, Small EJ, Gleave ME. PMID: 29206995; PMCID: PMC6440274.
      View in: PubMed   Mentions: 163     Fields:    Translation:HumansCells
    72. Genomic Markers in Prostate Cancer Decision Making. Eur Urol. 2018 04; 73(4):572-582. Cucchiara V, Cooperberg MR, Dall'Era M, Lin DW, Montorsi F, Schalken JA, Evans CP. PMID: 29129398.
      View in: PubMed   Mentions: 102     Fields:    Translation:Humans
    73. Impact of lymph node dissection at the time of radical nephrectomy with tumor thrombectomy on oncological outcomes: Results from the International Renal Cell Carcinoma-Venous Thrombus Consortium (IRCC-VTC). Urol Oncol. 2018 02; 36(2):79.e11-79.e17. Tilki D, Chandrasekar T, Capitanio U, Ciancio G, Daneshmand S, Gontero P, Gonzalez J, Haferkamp A, Hohenfellner M, Huang WC, Linares Espinós E, Lorentz A, Martinez-Salamanca JI, Master VA, McKiernan JM, Montorsi F, Novara G, Pahernik S, Palou J, Pruthi RS, Rodriguez-Faba O, Russo P, Scherr DS, Shariat SF, Spahn M, Terrone C, Vera-Donoso C, Zigeuner R, Libertino JA, Evans CP. PMID: 29129353; PMCID: PMC8404533.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    74. TMPRSS2-ERG fusions unexpectedly identified in men initially diagnosed with nonprostatic malignancies. JCO Precis Oncol. 2017; 2017. Lara PN, Heilmann AM, Elvin JA, Parikh M, de Vere White R, Gandour-Edwards R, Evans CP, Pan CX, Schrock AB, Erlich R, Ross JS, Stephens PJ, McPherson J, Miller VA, Ali SM. PMID: 29629426; PMCID: PMC5884164.
      View in: PubMed   Mentions: 7     Fields:    
    75. A contemporary population-based study of testicular sex cord stromal tumours: Presentation, treatment patterns, and predictors of outcome. Can Urol Assoc J. 2017 Sep; 11(9):E344-E349. Yuh LM, Lara PN, Wagenaar RM, Evans CP, Dall'era MA, Cress R, Yap SA. PMID: 29382456; PMCID: PMC5798438.
      View in: PubMed   Mentions: 2  
    76. The Promise and Disappointment of Neoadjuvant Chemotherapy and Transurethral Resection for Muscle Invasive Bladder Cancer: Updated Results and Long-Term Followup. Urol Pract. 2018 Jul; 5(4):305-310. Yap SA, Pugashetti N, Chandrasekar T, Dall'Era MA, Evans CP, Lara PN, deVere White RW. PMID: 37312295.
      View in: PubMed   Mentions:
    77. Utility of Anterior Zone Biopsy in Men Enrolled in Active Surveillance for Prostate Cancer. Clin Genitourin Cancer. 2017 Jul 14. Glass AS, Pugashetti NB, Dall'Era MA, Evans CP, Yap SA. PMID: 28789835.
      View in: PubMed   Mentions:    Fields:    
    78. ABCB1 Mediates Cabazitaxel-Docetaxel Cross-Resistance in Advanced Prostate Cancer. Mol Cancer Ther. 2017 10; 16(10):2257-2266. Lombard AP, Liu C, Armstrong CM, Cucchiara V, Gu X, Lou W, Evans CP, Gao AC. PMID: 28698198; PMCID: PMC5628132.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansCells
    79. Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. Eur Urol. 2018 02; 73(2):178-211. Gillessen S, Attard G, Beer TM, Beltran H, Bossi A, Bristow R, Carver B, Castellano D, Chung BH, Clarke N, Daugaard G, Davis ID, de Bono J, Borges Dos Reis R, Drake CG, Eeles R, Efstathiou E, Evans CP, Fanti S, Feng F, Fizazi K, Frydenberg M, Gleave M, Halabi S, Heidenreich A, Higano CS, James N, Kantoff P, Kellokumpu-Lehtinen PL, Khauli RB, Kramer G, Logothetis C, Maluf F, Morgans AK, Morris MJ, Mottet N, Murthy V, Oh W, Ost P, Padhani AR, Parker C, Pritchard CC, Roach M, Rubin MA, Ryan C, Saad F, Sartor O, Scher H, Sella A, Shore N, Smith M, Soule H, Sternberg CN, Suzuki H, Sweeney C, Sydes MR, Tannock I, Tombal B, Valdagni R, Wiegel T, Omlin A. PMID: 28655541.
      View in: PubMed   Mentions: 184     Fields:    Translation:Humans
    80. MicroRNA-181a promotes docetaxel resistance in prostate cancer cells. Prostate. 2017 Jun; 77(9):1020-1028. Armstrong CM, Liu C, Lou W, Lombard AP, Evans CP, Gao AC. PMID: 28485104; PMCID: PMC5448975.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCells
    81. Niclosamide and Bicalutamide Combination Treatment Overcomes Enzalutamide- and Bicalutamide-Resistant Prostate Cancer. Mol Cancer Ther. 2017 08; 16(8):1521-1530. Liu C, Armstrong CM, Lou W, Lombard AP, Cucchiara V, Gu X, Yang JC, Nadiminty N, Pan CX, Evans CP, Gao AC. PMID: 28500234; PMCID: PMC5544572.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansAnimalsCells
    82. The Decipher Genomic Classifier Independently Improves Prognostication for Patients After Prostatectomy. Eur Urol. 2018 02; 73(2):176-177. Tilki D, Evans CP. PMID: 28456348.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    83. Adjunct Screening of NKX3.1 Expression Supports 5α-Reductase Inhibition Intervention in Prostate Cancer Active Surveillance. Eur Urol. 2017 10; 72(4):507-508. Yang JC, Evans CP. PMID: 28454662.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    84. Impact of Microscopic Wall Invasion of the Renal Vein or Inferior Vena Cava on Cancer-specific Survival in Patients with Renal Cell Carcinoma and Tumor Thrombus: A Multi-institutional Analysis from the International Renal Cell Carcinoma-Venous Thrombus Consortium. Eur Urol Focus. 2018 04; 4(3):435-441. Rodriguez Faba O, Linares E, Tilki D, Capitanio U, Evans CP, Montorsi F, Martínez-Salamanca JI, Libertino J, Gontero P, Palou J. PMID: 28753848.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    85. Epigenomic Regulation of Androgen Receptor Signaling: Potential Role in Prostate Cancer Therapy. Cancers (Basel). 2017 Jan 16; 9(1). Cucchiara V, Yang JC, Mirone V, Gao AC, Rosenfeld MG, Evans CP. PMID: 28275218; PMCID: PMC5295780.
      View in: PubMed   Mentions: 16  
    86. Understanding Mechanisms of Resistance in Metastatic Castration-resistant Prostate Cancer: The Role of the Androgen Receptor. Eur Urol Focus. 2016 Dec; 2(5):499-505. Tilki D, Schaeffer EM, Evans CP. PMID: 28723515.
      View in: PubMed   Mentions: 30     Fields:    
    87. Targeting Adaptive Pathways in Metastatic Treatment-Resistant Prostate Cancer: Update on the Stand Up 2 Cancer/Prostate Cancer Foundation-Supported West Coast Prostate Cancer Dream Team. Eur Urol Focus. 2016 Dec; 2(5):469-471. Aggarwal R, Beer TM, Gleave M, Stuart JM, Rettig M, Evans CP, Youngren J, Alumkal JJ, Huang J, Thomas G, Witte O, Small EJ. PMID: 28723508.
      View in: PubMed   Mentions: 9     Fields:    
    88. Inhibition of AKR1C3 Activation Overcomes Resistance to Abiraterone in Advanced Prostate Cancer. Mol Cancer Ther. 2017 01; 16(1):35-44. Liu C, Armstrong CM, Lou W, Lombard A, Evans CP, Gao AC. PMID: 27794047; PMCID: PMC5222693.
      View in: PubMed   Mentions: 54     Fields:    Translation:HumansAnimalsCells
    89. Effect of Neoadjuvant Chemotherapy on Renal Function following Radical Cystectomy: Is there a Meaningful Impact? Bladder Cancer. 2016 Oct 27; 2(4):441-448. Chandrasekar T, Pugashetti N, Durbin-Johnson B, Dall'Era MA, Evans CP, deVere White RW, Yap SA. PMID: 28035325; PMCID: PMC5181664.
      View in: PubMed   Mentions: 2  
    90. Genomic and Biological Markers to Select Treatment for Patients with Prostate Cancer: Choose Wisely, My Friend. J Urol. 2017 01; 197(1):8-9. Dall'Era M, Evans C. PMID: 27746279.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    91. Renal cell carcinoma with inferior vena cava involvement: Prognostic effect of tumor thrombus consistency on cancer specific survival. J Surg Oncol. 2016 Nov; 114(6):764-768. Mager R, Daneshmand S, Evans CP, Palou J, Martínez-Salamanca JI, Master VA, McKiernan JM, Libertino JA, Haferkamp A, International Renal Cell Carcinoma-Venous Thrombus Consortium, Haferkamp A, Capitanio U, Carballido JA, Chantada V, Chromecki T, Ciancio G, Daneshmand S, Evans CP, Gontero P, González J, Hohenfellner M, Huang WC, Koppie TM, Libertino JA, Espinós EL, Lorentz A, Martínez-Salamanca JI, Master VA, McKiernan JM, Montorsi F, Novara G, O'Malley P, Pahernik S, Palou J, Moreno JL, Pruthi RS, Faba OR, Russo P, Scherr DS, Shariat SF, Spahn M, Terrone C, Tilki D, Vázquez-Martul D, Donoso CV, Vergho D, Wallen EM, Zigeuner R. PMID: 27562252; PMCID: PMC5560037.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    92. Re: Clinical Outcomes for Patients with Gleason Score 9-10 Prostate Adenocarcinoma Treated With Radiotherapy or Radical Prostatectomy: A Multi-institutional Comparative Analysis. Eur Urol. 2016 12; 70(6):1079-1080. Tilki D, Evans CP. PMID: 27567208.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    93. Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study. Eur Urol. 2017 02; 71(2):151-154. Beer TM, Armstrong AJ, Rathkopf D, Loriot Y, Sternberg CN, Higano CS, Iversen P, Evans CP, Kim CS, Kimura G, Miller K, Saad F, Bjartell AS, Borre M, Mulders P, Tammela TL, Parli T, Sari S, van Os S, Theeuwes A, Tombal B. PMID: 27477525; PMCID: PMC5570461.
      View in: PubMed   Mentions: 148     Fields:    Translation:HumansCTClinical Trials
    94. Evolving patterns of care in the management of stage I non-seminomatous germ cell tumors: data from the California Cancer Registry. World J Urol. 2017 Feb; 35(2):277-283. Yap SA, Yuh LM, Evans CP, Dall'Era MA, Wagenaar RM, Cress R, Lara PN. PMID: 27306686.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    95. Perioperative Outcomes following Neoadjuvant Chemotherapy and Radical Cystectomy-Is There Room for Improvement? Urol Pract. 2016 Sep; 3(5):364-370. Pugashetti N, Chandrasekar T, Lurvey R, Durbin-Johnson B, Dall'Era MA, deVere White RW, Evans CP, Yap SA. PMID: 37592562.
      View in: PubMed   Mentions:
    96. Autophagy and urothelial carcinoma of the bladder: A review. Investig Clin Urol. 2016 06; 57 Suppl 1:S89-97. Chandrasekar T, Evans CP. PMID: 27326411; PMCID: PMC4910764.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    97. Corrigendum: ROR-γ drives androgen receptor expression and represents a therapeutic target in castration-resistant prostate cancer. Nat Med. 2016 06 07; 22(6):692. Wang J, Zou JX, Xue X, Cai D, Zhang Y, Duan Z, Xiang Q, Yang JC, Louie MC, Borowsky AD, Gao AC, Evans CP, Lam KS, Xu J, Kung HJ, Evans RM, Xu Y, Chen HW. PMID: 27270780.
      View in: PubMed   Mentions: 5     Fields:    
    98. Surgery Provides Better Oncologic Outcomes than Radiation for the Treatment of Prostate Cancer. J Urol. 2016 08; 196(2):309-11. Klotz L, Evans CP. PMID: 27164513.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    99. A phase 2 clinical trial of everolimus plus bicalutamide for castration-resistant prostate cancer. Cancer. 2016 06 15; 122(12):1897-904. Chow H, Ghosh PM, deVere White R, Evans CP, Dall'Era MA, Yap SA, Li Y, Beckett LA, Lara PN, Pan CX. PMID: 27019001; PMCID: PMC4892938.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansCTClinical Trials
    100. ROR-γ drives androgen receptor expression and represents a therapeutic target in castration-resistant prostate cancer. Nat Med. 2016 05; 22(5):488-96. Wang J, Zou JX, Xue X, Cai D, Zhang Y, Duan Z, Xiang Q, Yang JC, Louie MC, Borowsky AD, Gao AC, Evans CP, Lam KS, Xu J, Kung HJ, Evans RM, Xu Y, Chen HW. PMID: 27019329; PMCID: PMC5030109.
      View in: PubMed   Mentions: 68     Fields:    Translation:HumansAnimalsCells
    101. The PREVAIL Study: Primary Outcomes by Site and Extent of Baseline Disease for Enzalutamide-treated Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer. Eur Urol. 2016 10; 70(4):675-683. Evans CP, Higano CS, Keane T, Andriole G, Saad F, Iversen P, Miller K, Kim CS, Kimura G, Armstrong AJ, Sternberg CN, Loriot Y, de Bono J, Noonberg SB, Mansbach H, Bhattacharya S, Perabo F, Beer TM, Tombal B. PMID: 27006332.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansCTClinical Trials
    102. Salvage radical prostatectomy: a few good men. BJU Int. 2016 Jan; 117(1):9-10. Chandrasekar T, Evans CP. PMID: 26676680.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    103. Lin28 induces resistance to anti-androgens via promotion of AR splice variant generation. Prostate. 2016 Apr; 76(5):445-55. Tummala R, Nadiminty N, Lou W, Evans CP, Gao AC. PMID: 26714839; PMCID: PMC5372699.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCells
    104. Hormonal Treatment for Nonmetastatic Disease Recurrence After Curative Treatment of Prostate Cancer: Only for a Select Few. Eur Urol. 2016 05; 69(5):821-2. Tilki D, Evans CP. PMID: 26719013.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    105. Urethral recurrence after cystectomy: current preventative measures, diagnosis and management. BJU Int. 2016 Apr; 117(4):563-9. Chan Y, Fisher P, Tilki D, Evans CP. PMID: 26556525.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    106. miR-124 and Androgen Receptor Signaling Inhibitors Repress Prostate Cancer Growth by Downregulating Androgen Receptor Splice Variants, EZH2, and Src. Cancer Res. 2015 Dec 15; 75(24):5309-17. Shi XB, Ma AH, Xue L, Li M, Nguyen HG, Yang JC, Tepper CG, Gandour-Edwards R, Evans CP, Kung HJ, deVere White RW. PMID: 26573802; PMCID: PMC4681619.
      View in: PubMed   Mentions: 35     Fields:    Translation:HumansAnimalsCells
    107. Targeting molecular resistance in castration-resistant prostate cancer. BMC Med. 2015 Sep 01; 13:206. Chandrasekar T, Yang JC, Gao AC, Evans CP. PMID: 26329698; PMCID: PMC4556222.
      View in: PubMed   Mentions: 28     Fields:    Translation:Humans
    108. NF-κB2/p52:c-Myc:hnRNPA1 Pathway Regulates Expression of Androgen Receptor Splice Variants and Enzalutamide Sensitivity in Prostate Cancer. Mol Cancer Ther. 2015 Aug; 14(8):1884-95. Nadiminty N, Tummala R, Liu C, Lou W, Evans CP, Gao AC. PMID: 26056150; PMCID: PMC4529751.
      View in: PubMed   Mentions: 69     Fields:    Translation:HumansCells
    109. Mechanisms of resistance in castration-resistant prostate cancer (CRPC). Transl Androl Urol. 2015 Jun; 4(3):365-80. Chandrasekar T, Yang JC, Gao AC, Evans CP. PMID: 26814148; PMCID: PMC4708226.
      View in: PubMed   Mentions: 242  
    110. Niclosamide suppresses cell migration and invasion in enzalutamide resistant prostate cancer cells via Stat3-AR axis inhibition. Prostate. 2015 Sep; 75(13):1341-53. Liu C, Lou W, Armstrong C, Zhu Y, Evans CP, Gao AC. PMID: 25970160; PMCID: PMC4536195.
      View in: PubMed   Mentions: 48     Fields:    Translation:HumansCells
    111. Active Surveillance for Prostate Cancer under the Patient Protection and Affordable Care Act. Urol Pract. 2015 Jul; 2(4):154-159. Yuh L, Dall'Era MA, Penson DF, Evans CP. PMID: 37559259.
      View in: PubMed   Mentions:
    112. Cardiopulmonary Bypass has No Significant Impact on Survival in Patients Undergoing Nephrectomy and Level III-IV Inferior Vena Cava Thrombectomy: Multi-Institutional Analysis. J Urol. 2015 Aug; 194(2):304-308. Nguyen HG, Tilki D, Dall'Era MA, Durbin-Johnson B, Carballido JA, Chandrasekar T, Chromecki T, Ciancio G, Daneshmand S, Gontero P, Gonzalez J, Haferkamp A, Hohenfellner M, Huang WC, Espinós EL, Mandel P, Martinez-Salamanca JI, Master VA, McKiernan JM, Montorsi F, Novara G, Pahernik S, Palou J, Pruthi RS, Rodriguez-Faba O, Russo P, Scherr DS, Shariat SF, Spahn M, Terrone C, Vergho D, Wallen EM, Xylinas E, Zigeuner R, Libertino JA, Evans CP. PMID: 25797392; PMCID: PMC5012645.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCells
    113. Intracrine Androgens and AKR1C3 Activation Confer Resistance to Enzalutamide in Prostate Cancer. Cancer Res. 2015 Apr 01; 75(7):1413-22. Liu C, Lou W, Zhu Y, Yang JC, Nadiminty N, Gaikwad NW, Evans CP, Gao AC. PMID: 25649766; PMCID: PMC4383695.
      View in: PubMed   Mentions: 135     Fields:    Translation:HumansAnimalsCells
    114. Targeted local therapy in oligometastatic prostate cancer: a promising potential opportunity after failed primary treatment. BJU Int. 2015 Aug; 116(2):170-2. Reeves F, Murphy D, Evans C, Bowden P, Costello A. PMID: 25308065.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    115. Ultrasensitive prostate specific antigen and its role after radical prostatectomy: a systematic review. J Urol. 2015 May; 193(5):1525-31. Tilki D, Kim SI, Hu B, Dall'Era MA, Evans CP. PMID: 25444980.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    116. Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level. Eur Urol. 2015 Mar; 67(3):470-9. Karantanos T, Evans CP, Tombal B, Thompson TC, Montironi R, Isaacs WB. PMID: 25306226; PMCID: PMC5301306.
      View in: PubMed   Mentions: 129     Fields:    Translation:HumansAnimalsCells
    117. Molecular pathways and targets in prostate cancer. Oncotarget. 2014 Sep 15; 5(17):7217-59. Shtivelman E, Beer TM, Evans CP. PMID: 25277175; PMCID: PMC4202120.
      View in: PubMed   Mentions: 56     Fields:    Translation:HumansAnimals
    118. Targeting Btk/Etk of prostate cancer cells by a novel dual inhibitor. Cell Death Dis. 2014 Sep 04; 5:e1409. Guo W, Liu R, Bhardwaj G, Yang JC, Changou C, Ma AH, Mazloom A, Chintapalli S, Xiao K, Xiao W, Kumaresan P, Sanchez E, Yeh CT, Evans CP, Patterson R, Lam KS, Kung HJ. PMID: 25188519; PMCID: PMC4540187.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansAnimalsCells
    119. Autophagy as a modulator and target in prostate cancer. Nat Rev Urol. 2014 Sep; 11(9):508-16. Farrow JM, Yang JC, Evans CP. PMID: 25134829; PMCID: PMC4415606.
      View in: PubMed   Mentions: 85     Fields:    Translation:Humans
    120. Impact of synchronous metastasis distribution on cancer specific survival in renal cell carcinoma after radical nephrectomy with tumor thrombectomy. J Urol. 2015 Feb; 193(2):436-42. Tilki D, Hu B, Nguyen HG, Dall'Era MA, Bertini R, Carballido JA, Chandrasekar T, Chromecki T, Ciancio G, Daneshmand S, Gontero P, Gonzalez J, Haferkamp A, Hohenfellner M, Huang WC, Koppie TM, Linares E, Lorentz CA, Mandel P, Martinez-Salamanca JI, Master VA, Matloob R, McKiernan JM, Mlynarczyk CM, Montorsi F, Novara G, Pahernik S, Palou J, Pruthi RS, Ramaswamy K, Rodriguez Faba O, Russo P, Shariat SF, Spahn M, Terrone C, Thieu W, Vergho D, Wallen EM, Xylinas E, Zigeuner R, Libertino JA, Evans CP. PMID: 25063493.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCells
    121. Prostate cancer: Predicting response to androgen receptor signalling inhibition. Nat Rev Urol. 2014 Aug; 11(8):433-5. Evans CP, Lara PN. PMID: 25048863.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    122. The role of microRNA in castration-resistant prostate cancer. Urol Oncol. 2014 Jul; 32(5):517-523. Thieu W, Tilki D, de Vere White R, Evans CP. PMID: 24935732; PMCID: PMC4570565.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    123. Chem-seq permits identification of genomic targets of drugs against androgen receptor regulation selected by functional phenotypic screens. Proc Natl Acad Sci U S A. 2014 Jun 24; 111(25):9235-40. Jin C, Yang L, Xie M, Lin C, Merkurjev D, Yang JC, Tanasa B, Oh S, Zhang J, Ohgi KA, Zhou H, Li W, Evans CP, Ding S, Rosenfeld MG. PMID: 24928520; PMCID: PMC4078819.
      View in: PubMed   Mentions: 38     Fields:    Translation:HumansAnimalsCells
    124. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014 Jul 31; 371(5):424-33. Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, Iversen P, Bhattacharya S, Carles J, Chowdhury S, Davis ID, de Bono JS, Evans CP, Fizazi K, Joshua AM, Kim CS, Kimura G, Mainwaring P, Mansbach H, Miller K, Noonberg SB, Perabo F, Phung D, Saad F, Scher HI, Taplin ME, Venner PM, Tombal B, PREVAIL Investigators. PMID: 24881730; PMCID: PMC4418931.
      View in: PubMed   Mentions: 1082     Fields:    Translation:HumansCTClinical Trials
    125. Lessons learned from the International Renal Cell Carcinoma-Venous Thrombus Consortium (IRCC-VTC). Curr Urol Rep. 2014 May; 15(5):404. Martínez-Salamanca JI, Linares E, González J, Bertini R, Carballido JA, Chromecki T, Ciancio G, Daneshmand S, Evans CP, Gontero P, Haferkamp A, Hohenfellner M, Huang WC, Koppie TM, Master VA, Matloob R, McKiernan JM, Mlynarczyk CM, Montorsi F, Nguyen HG, Novara G, Pahernik S, Palou J, Pruthi RS, Ramaswamy K, Faba OR, Russo P, Shariat SF, Spahn M, Terrone C, Tilki D, Vergho D, Wallen EM, Xylinas E, Zigeuner R, Libertino JA. PMID: 24682884.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCells
    126. Niclosamide inhibits androgen receptor variants expression and overcomes enzalutamide resistance in castration-resistant prostate cancer. Clin Cancer Res. 2014 Jun 15; 20(12):3198-3210. Liu C, Lou W, Zhu Y, Nadiminty N, Schwartz CT, Evans CP, Gao AC. PMID: 24740322; PMCID: PMC4058390.
      View in: PubMed   Mentions: 188     Fields:    Translation:HumansAnimalsCells
    127. The changing landscape of advanced and castration resistant prostate cancer: latest science and revised definitions. Can J Urol. 2014 Apr; 21(2 Supp 1):7-13. Tilki D, Evans CP. PMID: 24775718.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    128. Targeting autophagy overcomes Enzalutamide resistance in castration-resistant prostate cancer cells and improves therapeutic response in a xenograft model. Oncogene. 2014 Sep 04; 33(36):4521-30. Nguyen HG, Yang JC, Kung HJ, Shi XB, Tilki D, Lara PN, DeVere White RW, Gao AC, Evans CP. PMID: 24662833; PMCID: PMC4155805.
      View in: PubMed   Mentions: 106     Fields:    Translation:HumansAnimalsCells
    129. No improvement noted in overall or cause-specific survival for men presenting with metastatic prostate cancer over a 20-year period. Cancer. 2014 Mar 15; 120(6):818-23. Wu JN, Fish KM, Evans CP, Devere White RW, Dall'Era MA. PMID: 24258693.
      View in: PubMed   Mentions: 59     Fields:    Translation:Humans
    130. Dasatinib and docetaxel in advanced prostate cancer. Lancet Oncol. 2013 Dec; 14(13):1248-9. Lara PN, Evans CP. PMID: 24211164.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    131. Inhibition of constitutively active Stat3 reverses enzalutamide resistance in LNCaP derivative prostate cancer cells. Prostate. 2014 Feb; 74(2):201-9. Liu C, Zhu Y, Lou W, Cui Y, Evans CP, Gao AC. PMID: 24307657; PMCID: PMC4437226.
      View in: PubMed   Mentions: 61     Fields:    Translation:HumansCells
    132. CTA095, a novel Etk and Src dual inhibitor, induces apoptosis in prostate cancer cells and overcomes resistance to Src inhibitors. PLoS One. 2013; 8(8):e70910. Guo W, Liu R, Bhardwaj G, Ma AH, Changou C, Yang JC, Li Y, Feng C, Luo Y, Mazloom A, Sanchez E, Wang Y, Huang W, Patterson R, Evans CP, Lam KS, Kung HJ. PMID: 23967135; PMCID: PMC3744530.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansAnimalsCells
    133. lncRNA-dependent mechanisms of androgen-receptor-regulated gene activation programs. Nature. 2013 Aug 29; 500(7464):598-602. Yang L, Lin C, Jin C, Yang JC, Tanasa B, Li W, Merkurjev D, Ohgi KA, Meng D, Zhang J, Evans CP, Rosenfeld MG. PMID: 23945587; PMCID: PMC4034386.
      View in: PubMed   Mentions: 360     Fields:    Translation:HumansAnimalsCells
    134. Inhibition of ABCB1 expression overcomes acquired docetaxel resistance in prostate cancer. Mol Cancer Ther. 2013 Sep; 12(9):1829-36. Zhu Y, Liu C, Nadiminty N, Lou W, Tummala R, Evans CP, Gao AC. PMID: 23861346; PMCID: PMC3947549.
      View in: PubMed   Mentions: 59     Fields:    Translation:HumansCells
    135. Impact of histologic subtype on cancer-specific survival in patients with renal cell carcinoma and tumor thrombus. Eur Urol. 2014 Sep; 66(3):577-83. Tilki D, Nguyen HG, Dall'Era MA, Bertini R, Carballido JA, Chromecki T, Ciancio G, Daneshmand S, Gontero P, Gonzalez J, Haferkamp A, Hohenfellner M, Huang WC, Koppie TM, Lorentz CA, Mandel P, Martinez-Salamanca JI, Master VA, Matloob R, McKiernan JM, Mlynarczyk CM, Montorsi F, Novara G, Pahernik S, Palou J, Pruthi RS, Ramaswamy K, Rodriguez Faba O, Russo P, Shariat SF, Spahn M, Terrone C, Vergho D, Wallen EM, Xylinas E, Zigeuner R, Libertino JA, Evans CP. PMID: 23871402.
      View in: PubMed   Mentions: 34     Fields:    Translation:Humans
    136. Lin28 promotes growth of prostate cancer cells and activates the androgen receptor. Am J Pathol. 2013 Jul; 183(1):288-95. Tummala R, Nadiminty N, Lou W, Zhu Y, Gandour-Edwards R, Chen HW, Evans CP, Gao AC. PMID: 23790802; PMCID: PMC3702743.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansAnimalsCells
    137. miR-30 as a tumor suppressor connects EGF/Src signal to ERG and EMT. Oncogene. 2014 May 08; 33(19):2495-503. Kao CJ, Martiniez A, Shi XB, Yang J, Evans CP, Dobi A, deVere White RW, Kung HJ. PMID: 23728339; PMCID: PMC4370229.
      View in: PubMed   Mentions: 83     Fields:    Translation:HumansAnimalsCells
    138. NF-κB2/p52 induces resistance to enzalutamide in prostate cancer: role of androgen receptor and its variants. Mol Cancer Ther. 2013 Aug; 12(8):1629-37. Nadiminty N, Tummala R, Liu C, Yang J, Lou W, Evans CP, Gao AC. PMID: 23699654; PMCID: PMC3941973.
      View in: PubMed   Mentions: 107     Fields:    Translation:HumansCells
    139. Lymphadenectomy for bladder cancer at the time of radical cystectomy. Eur Urol. 2013 Aug; 64(2):266-76. Tilki D, Brausi M, Colombo R, Evans CP, Fradet Y, Fritsche HM, Lerner SP, Sagalowsky A, Shariat SF, Bochner BH. PMID: 23648149.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    140. Autophagy and Prostate Cancer Therapeutics. . 2013 Jan 1; 497-518. Kung KH, Changou CC, Nguyen NH, Yang YJ, Evans EC, Bold BR, Chuang CF. .
      View in: Publisher Site   Mentions:
    141. CRM1 blockade by selective inhibitors of nuclear export attenuates kidney cancer growth. J Urol. 2013 Jun; 189(6):2317-26. Inoue H, Kauffman M, Shacham S, Landesman Y, Yang J, Evans CP, Weiss RH. PMID: 23079374; PMCID: PMC4593314.
      View in: PubMed   Mentions: 62     Fields:    Translation:HumansAnimalsCells
    142. Histopathology of surgically treated renal cell carcinoma: survival differences by subtype and stage. J Urol. 2012 Aug; 188(2):391-7. Keegan KA, Schupp CW, Chamie K, Hellenthal NJ, Evans CP, Koppie TM. PMID: 22698625; PMCID: PMC3714400.
      View in: PubMed   Mentions: 85     Fields:    Translation:Humans
    143. Kidney tumor biomarkers revealed by simultaneous multiple matrix metabolomics analysis. Cancer Res. 2012 Jul 15; 72(14):3471-9. Ganti S, Taylor SL, Abu Aboud O, Yang J, Evans C, Osier MV, Alexander DC, Kim K, Weiss RH. PMID: 22628425; PMCID: PMC3399039.
      View in: PubMed   Mentions: 56     Fields:    Translation:HumansAnimalsCells
    144. Economic analysis of active surveillance for localized prostate cancer. Curr Opin Urol. 2012 May; 22(3):247-53. Kim S, Dall'Era MA, Evans CP. PMID: 22388666.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansPHPublic Health
    145. MicroRNA let-7c is downregulated in prostate cancer and suppresses prostate cancer growth. PLoS One. 2012; 7(3):e32832. Nadiminty N, Tummala R, Lou W, Zhu Y, Shi XB, Zou JX, Chen H, Zhang J, Chen X, Luo J, deVere White RW, Kung HJ, Evans CP, Gao AC. PMID: 22479342; PMCID: PMC3316551.
      View in: PubMed   Mentions: 88     Fields:    Translation:HumansAnimalsCells
    146. Defining an individualized treatment strategy for metastatic renal cancer. Urol Clin North Am. 2012 May; 39(2):233-49, vii. Hu B, Lara PN, Evans CP. PMID: 22487765.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    147. The Economics of Active Surveillance for Prostate Cancer. . 2012 Jan 1; 179-185. Dall’Era DM, Evans EC. .
      View in: Publisher Site   Mentions:
    148. Active surveillance for prostate cancer compared with immediate treatment: an economic analysis. Cancer. 2012 Jul 15; 118(14):3512-8. Keegan KA, Dall'Era MA, Durbin-Johnson B, Evans CP. PMID: 22180322; PMCID: PMC3698480.
      View in: PubMed   Mentions: 30     Fields:    Translation:Humans
    149. MicroRNA let-7c suppresses androgen receptor expression and activity via regulation of Myc expression in prostate cancer cells. J Biol Chem. 2012 Jan 06; 287(2):1527-37. Nadiminty N, Tummala R, Lou W, Zhu Y, Zhang J, Chen X, eVere White RW, Kung HJ, Evans CP, Gao AC. PMID: 22128178; PMCID: PMC3256915.
      View in: PubMed   Mentions: 99     Fields:    Translation:HumansCells
    150. Pretreatment imaging can be used to select imaging guidance, ultrasound alone versus CT plus ultrasound, for percutaneous renal radiofrequency ablation. AJR Am J Roentgenol. 2011 Nov; 197(5):1244-50. McGahan JP, Loh S, Fitzgerald E, Koppie T, Evans CP, Dall'Era M, Li CS. PMID: 22021521.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    151. Traditional approaches to androgen deprivation therapy. Urology. 2011 Nov; 78(5 Suppl):S485-93. Moul JW, Evans CP, Gomella LG, Roach M, Dreicer R. PMID: 22054920.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    152. Urinary acylcarnitines are altered in human kidney cancer. Int J Cancer. 2012 Jun 15; 130(12):2791-800. Ganti S, Taylor SL, Kim K, Hoppel CL, Guo L, Yang J, Evans C, Weiss RH. PMID: 21732340; PMCID: PMC3258465.
      View in: PubMed   Mentions: 65     Fields:    Translation:HumansAnimalsCells
    153. Simultaneous targeting of Src kinase and receptor tyrosine kinase results in synergistic inhibition of renal cell carcinoma proliferation and migration. Int J Cancer. 2012 Jun 01; 130(11):2693-702. Bai L, Yang JC, Ok JH, Mack PC, Kung HJ, Evans CP. PMID: 21792888.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCells
    154. RhoGDIα suppresses growth and survival of prostate cancer cells. Prostate. 2012 Mar; 72(4):392-8. Zhu Y, Tummala R, Liu C, Nadiminty N, Lou W, Evans CP, Zhou Q, Gao AC. PMID: 21681778; PMCID: PMC3961824.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansAnimalsCells
    155. Effect of age on transitional cell carcinoma of the upper urinary tract: presentation, treatment, and outcomes. Urology. 2011 Jul; 78(1):87-92. Yap SA, Schupp CW, Chamie K, Evans CP, Koppie TM. PMID: 21601253.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    156. Inhibition of Stat3 activation by sanguinarine suppresses prostate cancer cell growth and invasion. Prostate. 2012 Jan; 72(1):82-9. Sun M, Liu C, Nadiminty N, Lou W, Zhu Y, Yang J, Evans CP, Zhou Q, Gao AC. PMID: 21538419; PMCID: PMC3938016.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansCells
    157. Palliative care in urology. Surg Clin North Am. 2011 Apr; 91(2):429-44, x. Wu JN, Meyers FJ, Evans CP. PMID: 21419262.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    158. Secondary malignancies among nonseminomatous germ cell tumor cancer survivors. Cancer. 2011 Sep 15; 117(18):4219-30. Chamie K, Kurzrock EA, Evans CP, Litwin MS, Koppie TM, Wootton-Gorges SL, Boone JM, Lara PN, Devere White RW. PMID: 21412759.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    159. MicroRNA in prostate, bladder, and kidney cancer: a systematic review. Eur Urol. 2011 May; 59(5):671-81. Catto JW, Alcaraz A, Bjartell AS, De Vere White R, Evans CP, Fussel S, Hamdy FC, Kallioniemi O, Mengual L, Schlomm T, Visakorpi T. PMID: 21296484.
      View in: PubMed   Mentions: 217     Fields:    Translation:Humans
    160. Andrographolide targets androgen receptor pathway in castration-resistant prostate cancer. Genes Cancer. 2011 Feb; 2(2):151-9. Liu C, Nadiminty N, Tummala R, Chun JY, Lou W, Zhu Y, Sun M, Evans CP, Zhou Q, Gao AC. PMID: 21779488; PMCID: PMC3111248.
      View in: PubMed   Mentions: 15  
    161. Analysis of the cytotoxic activity of carboplatin and gemcitabine combination. Anticancer Res. 2010 Nov; 30(11):4573-8. Wang S, Zhang H, Cheng L, Evans C, Pan CX. PMID: 21115908; PMCID: PMC4562399.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCells
    162. Identification of a bladder cancer-specific ligand using a combinatorial chemistry approach. Urol Oncol. 2012 Sep; 30(5):635-45. Zhang H, Aina OH, Lam KS, de Vere White R, Evans C, Henderson P, Lara PN, Wang X, Bassuk JA, Pan CX. PMID: 20888272; PMCID: PMC4572726.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansAnimalsCells
    163. What is the optimal management of high risk, clinically localized prostate cancer? Urol Oncol. 2010 Sep-Oct; 28(5):557-67. Eastham JA, Evans CP, Zietman A. PMID: 20816616.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    164. Andrographolide, an herbal medicine, inhibits interleukin-6 expression and suppresses prostate cancer cell growth. Genes Cancer. 2010 Aug; 1(8):868-76. Chun JY, Tummala R, Nadiminty N, Lou W, Liu C, Yang J, Evans CP, Zhou Q, Gao AC. PMID: 21442031; PMCID: PMC3063649.
      View in: PubMed   Mentions: 20  
    165. Effect of the specific Src family kinase inhibitor saracatinib on osteolytic lesions using the PC-3 bone model. Mol Cancer Ther. 2010 Jun; 9(6):1629-37. Yang JC, Bai L, Yap S, Gao AC, Kung HJ, Evans CP. PMID: 20484016.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansAnimalsCells
    166. Aberrant activation of the androgen receptor by NF-kappaB2/p52 in prostate cancer cells. Cancer Res. 2010 Apr 15; 70(8):3309-19. Nadiminty N, Lou W, Sun M, Chen J, Yue J, Kung HJ, Evans CP, Zhou Q, Gao AC. PMID: 20388792; PMCID: PMC3041633.
      View in: PubMed   Mentions: 53     Fields:    Translation:HumansCells
    167. Sanguinarine suppresses prostate tumor growth and inhibits survivin expression. Genes Cancer. 2010 Mar; 1(3):283-92. Sun M, Lou W, Chun JY, Cho DS, Nadiminty N, Evans CP, Chen J, Yue J, Zhou Q, Gao AC. PMID: 21318089; PMCID: PMC3036540.
      View in: PubMed   Mentions: 21  
    168. Autophagy Blockade Sensitizes Prostate Cancer Cells towards Src Family Kinase Inhibitors. Genes Cancer. 2010 Jan; 1(1):40-9. Wu Z, Chang PC, Yang JC, Chu CY, Wang LY, Chen NT, Ma AH, Desai SJ, Lo SH, Evans CP, Lam KS, Kung HJ. PMID: 20811583; PMCID: PMC2930266.
      View in: PubMed   Mentions: 89  
    169. The role of surveillance in the treatment of patients with muscle-invasive bladder cancer after chemotherapy. BJU Int. 2010 Feb; 105(4):485-8. Hellenthal NJ, Ramirez ML, Evans CP, Devere White RW. PMID: 19849694.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    170. Interleukin-6 regulates androgen synthesis in prostate cancer cells. Clin Cancer Res. 2009 Aug 01; 15(15):4815-22. Chun JY, Nadiminty N, Dutt S, Lou W, Yang JC, Kung HJ, Evans CP, Gao AC. PMID: 19638459; PMCID: PMC3041150.
      View in: PubMed   Mentions: 53     Fields:    Translation:HumansAnimalsCells
    171. Adjuvant chemotherapy for high risk upper tract urothelial carcinoma: results from the Upper Tract Urothelial Carcinoma Collaboration. J Urol. 2009 Sep; 182(3):900-6. Hellenthal NJ, Shariat SF, Margulis V, Karakiewicz PI, Roscigno M, Bolenz C, Remzi M, Weizer A, Zigeuner R, Bensalah K, Ng CK, Raman JD, Kikuchi E, Montorsi F, Oya M, Wood CG, Fernandez M, Evans CP, Koppie TM. PMID: 19616245.
      View in: PubMed   Mentions: 58     Fields:    Translation:Humans
    172. Trends in pelvic lymphadenectomy at the time of radical cystectomy: 1988 to 2004. J Urol. 2009 Jun; 181(6):2490-5. Hellenthal NJ, Ramírez ML, Evans CP, deVere White RW, Koppie TM. PMID: 19371902.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    173. The Src inhibitor AZD0530 blocks invasion and may act as a radiosensitizer in lung cancer cells. J Thorac Oncol. 2009 Apr; 4(4):448-54. Purnell PR, Mack PC, Tepper CG, Evans CP, Green TP, Gumerlock PH, Lara PN, Gandara DR, Kung HJ, Gautschi O. PMID: 19240653; PMCID: PMC2716757.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCells
    174. A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study. Anticancer Drugs. 2009 Mar; 20(3):179-84. Lara PN, Longmate J, Evans CP, Quinn DI, Twardowski P, Chatta G, Posadas E, Stadler W, Gandara DR. PMID: 19396016; PMCID: PMC3225398.
      View in: PubMed   Mentions: 52     Fields:    Translation:HumansCTClinical Trials
    175. Interleukin-6 increases prostate cancer cells resistance to bicalutamide via TIF2. Mol Cancer Ther. 2009 Mar; 8(3):665-71. Feng S, Tang Q, Sun M, Chun JY, Evans CP, Gao AC. PMID: 19240160; PMCID: PMC3041173.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansCells
    176. Oncogenic activation of androgen receptor. Urol Oncol. 2009 Jan-Feb; 27(1):48-52. Kung HJ, Evans CP. PMID: 19111798; PMCID: PMC2629789.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCells
    177. Aberrant activation of androgen receptor in a new neuropeptide-autocrine model of androgen-insensitive prostate cancer. Cancer Res. 2009 Jan 01; 69(1):151-60. Yang JC, Ok JH, Busby JE, Borowsky AD, Kung HJ, Evans CP. PMID: 19117998; PMCID: PMC2626435.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansAnimalsCells
    178. SUO/SBUR 2007 annual meeting proceedings: overview. Urol Oncol. 2009 Jan-Feb; 27(1):33. Evans CP. PMID: 19111794.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    179. Identification of molecular targets in urologic oncology. World J Urol. 2009 Feb; 27(1):3-8. Evans CP. PMID: 19002690.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    180. Src family kinase oncogenic potential and pathways in prostate cancer as revealed by AZD0530. Oncogene. 2008 Oct 23; 27(49):6365-75. Chang YM, Bai L, Liu S, Yang JC, Kung HJ, Evans CP. PMID: 18679417; PMCID: PMC4294546.
      View in: PubMed   Mentions: 84     Fields:    Translation:HumansCells
    181. Editorial Comment. The Journal of Urology. 2008 Jun 1; 179(6):2202. Evans EC. .
      View in: Publisher Site   Mentions:
    182. Editorial Comment. The Journal of Urology. 2008 Jun 1; 179(6):2349-2350. Evans EC. .
      View in: Publisher Site   Mentions:
    183. Current applications for prostate-specific antigen doubling time. Eur Urol. 2008 Aug; 54(2):291-300. Ramírez ML, Nelson EC, Devere White RW, Lara PN, Evans CP. PMID: 18439749.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    184. Regulation of Id1 expression by SRC: implications for targeting of the bone morphogenetic protein pathway in cancer. Cancer Res. 2008 Apr 01; 68(7):2250-8. Gautschi O, Tepper CG, Purnell PR, Izumiya Y, Evans CP, Green TP, Desprez PY, Lara PN, Gandara DR, Mack PC, Kung HJ. PMID: 18381431.
      View in: PubMed   Mentions: 44     Fields:    Translation:HumansCells
    185. Beyond prostate-specific antigen: alternate serum markers. Prostate Cancer Prostatic Dis. 2008; 11(3):216-29. Ramírez ML, Nelson EC, Evans CP. PMID: 18227856.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    186. Non-surgical management of multicystic dysplastic kidney. BJU Int. 2008 Apr; 101(7):804-8. Cambio AJ, Evans CP, Kurzrock EA. PMID: 18190645.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    187. The interaction of genetic polymorphisms with lifestyle factors: implications for the dietary prevention of prostate cancer. Nutr Cancer. 2008; 60(3):301-12. Nelson EC, Rodriguez RL, Dawson K, Galvez AF, Evans CP. PMID: 18444164.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    188. An androgen-regulated miRNA suppresses Bak1 expression and induces androgen-independent growth of prostate cancer cells. Proc Natl Acad Sci U S A. 2007 Dec 11; 104(50):19983-8. Shi XB, Xue L, Yang J, Ma AH, Zhao J, Xu M, Tepper CG, Evans CP, Kung HJ, deVere White RW. PMID: 18056640; PMCID: PMC2148409.
      View in: PubMed   Mentions: 230     Fields:    Translation:HumansCells
    189. The AKT inhibitor perifosine in biochemically recurrent prostate cancer: a phase II California/Pittsburgh cancer consortium trial. Clin Genitourin Cancer. 2007 Dec; 5(7):433-7. Chee KG, Longmate J, Quinn DI, Chatta G, Pinski J, Twardowski P, Pan CX, Cambio A, Evans CP, Gandara DR, Lara PN. PMID: 18272025.
      View in: PubMed   Mentions: 38     Fields:    Translation:HumansCTClinical Trials
    190. Managing prostate cancer: the role of hormone therapy. Can J Urol. 2007 Dec; 14 Suppl 1:10-8. Ramirez ML, Keane TE, Evans CP. PMID: 18163939.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    191. Current management of small renal masses. Can J Urol. 2007 Dec; 14 Suppl 1:39-47. Ramírez ML, Evans CP. PMID: 18163944.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    192. Editorial comment on: Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder cancer. Eur Urol. 2007 Oct; 52(4):1129-30. Evans CP. PMID: 17383082.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    193. Prostate cancer and markers of bone metabolism: diagnostic, prognostic, and therapeutic implications. World J Urol. 2007 Aug; 25(4):393-9. Nelson EC, Evans CP, Pan CX, Lara PN. PMID: 17562051.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    194. Cost-benefit and outcome analysis: effect of prostate biopsy undergrading. Urology. 2007 Jun; 69(6):1152-6. Cambio AJ, Ellison LM, Chamie K, deVere White RW, Evans CP. PMID: 17572205.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    195. Inhibition of Akt pathways in the treatment of prostate cancer. Prostate Cancer Prostatic Dis. 2007; 10(4):331-9. Nelson EC, Evans CP, Mack PC, Devere-White RW, Lara PN. PMID: 17471291.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCells
    196. Bladder Cancer: Management and Future Directions. European Urology Supplements. 2007 Mar 1; 6(3):365-373. Evans EC, Debruyne DF, Payne PH, Solsona SE, Teillac TP, Tubaro TA. .
      View in: Publisher Site   Mentions:
    197. Current and Future Trends in the Treatment of Renal Cancer. European Urology Supplements. 2007 Mar 1; 6(3):374-384. Keane KT, Gillatt GD, Evans EC, Tubaro TA. .
      View in: Publisher Site   Mentions:
    198. The Continuing Role of PSA in the Detection and Management of Prostate Cancer. European Urology Supplements. 2007 Mar 1; 6(3):327-333. Miller MK, Abrahamsson AP, Akakura AK, Debruyne DF, Evans EC, Klotz KL. .
      View in: Publisher Site   Mentions:
    199. Outcomes and quality of life issues in the pharmacological management of benign prostatic hyperplasia (BPH). Ther Clin Risk Manag. 2007 Mar; 3(1):181-96. Cambio AJ, Evans CP. PMID: 18360626; PMCID: PMC1936299.
      View in: PubMed   Mentions: 4  
    200. Renal cell carcinoma: current status and emerging therapies. Cancer Treat Rev. 2007 May; 33(3):299-313. Nelson EC, Evans CP, Lara PN. PMID: 17329029.
      View in: PubMed   Mentions: 41     Fields:    Translation:Humans
    201. Nonreceptor tyrosine kinases in prostate cancer. Neoplasia. 2007 Feb; 9(2):90-100. Chang YM, Kung HJ, Evans CP. PMID: 17357254; PMCID: PMC1813931.
      View in: PubMed   Mentions: 66     Fields:    Translation:HumansCells
    202. Biologic agents as adjunctive therapy for prostate cancer: a rationale for use with androgen deprivation. Nat Clin Pract Urol. 2007 Feb; 4(2):82-94. Nelson EC, Cambio AJ, Yang JC, Lara PN, Evans CP. PMID: 17287869.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    203. Clinical implications of neuroendocrine differentiation in prostate cancer. Prostate Cancer Prostatic Dis. 2007; 10(1):6-14. Nelson EC, Cambio AJ, Yang JC, Ok JH, Lara PN, Evans CP. PMID: 17075603.
      View in: PubMed   Mentions: 34     Fields:    Translation:HumansAnimals
    204. Minimising postoperative incontinence following radical prostatectomy: considerations and evidence. Eur Urol. 2006 Nov; 50(5):903-13; discussion 913. Cambio AJ, Evans CP. PMID: 16956715.
      View in: PubMed   Mentions: 35     Fields:    Translation:Humans
    205. Editorial Comment. The Journal of Urology. 2006 Aug 1; 176(2):580. Evans EC. .
      View in: Publisher Site   Mentions:
    206. Efficacy of transhepatic radiofrequency ablation of renal cell carcinoma. AJR Am J Roentgenol. 2006 May; 186(5 Suppl):S311-5. McGahan JP, Ro KM, Evans CP, Ellison LM. PMID: 16632693.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    207. Management approaches to small renal tumours. BJU Int. 2006 Mar; 97(3):456-60. Cambio AJ, Evans CP. PMID: 16469007.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    208. Medical and surgical palliative care of patients with urological malignancies. J Urol. 2005 Oct; 174(4 Pt 1):1177-82. Ok JH, Meyers FJ, Evans CP. PMID: 16145365.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    209. Is the use of anything but MVAC justified in the evidence-based medicine era? Curr Opin Urol. 2005 Sep; 15(5):312-4. Ok JH, Cambio A, Lara PN, Evans CP. PMID: 16093854.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    210. An evidence-based approach to understanding the pharmacological class effect in the management of prostatic diseases. BJU Int. 2005 Apr; 95(6):743-9. Evans CP, Fleshner N, Fitzpatrick JM, Zlotta AR. PMID: 15794775.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    211. Society of Urologic Oncology position statement: redefining the management of hormone-refractory prostate carcinoma. Cancer. 2005 Jan 01; 103(1):11-21. Chang SS, Benson MC, Campbell SC, Crook J, Dreicer R, Evans CP, Hall MC, Higano C, Kelly WK, Sartor O, Smith JA, Society of Urologic Oncology, Shaumberg, Illinois. PMID: 15558815.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    212. Re: the economic burden of metastatic and prostate specific antigen progression in patients with prostate cancer: findings from a retrospective analysis of health plan data. J Urol. 2004 Dec; 172(6 Pt 1):2484. Pitts WR. PMID: 15538302.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    213. Old friends, new ways: revisiting extended lymphadenectomy and neoadjuvant chemotherapy to improve outcomes. Curr Opin Urol. 2004 Sep; 14(5):251-7. Busby JE, Evans CP. PMID: 15300144.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    214. Evidence-based medicine for the urologist. BJU Int. 2004 Jul; 94(1):1-2. Evans CP. PMID: 15217418.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    215. The economic burden of metastatic and prostate specific antigen progression in patients with prostate cancer: findings from a retrospective analysis of health plan data. J Urol. 2004 Jun; 171(6 Pt 1):2250-4. Penson DF, Moul JW, Evans CP, Doyle JJ, Gandhi S, Lamerato L. PMID: 15126796.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    216. Interleukin-8 confers androgen-independent growth and migration of LNCaP: differential effects of tyrosine kinases Src and FAK. Oncogene. 2004 Mar 18; 23(12):2197-205. Lee LF, Louie MC, Desai SJ, Yang J, Chen HW, Evans CP, Kung HJ. PMID: 14767470.
      View in: PubMed   Mentions: 70     Fields:    Translation:HumansCells
    217. Testicular cancer metastatic exclusively to the brain and spleen. Urology. 2004 Jan; 63(1):176-8. Nguyen MM, Corr AS, Evans CP. PMID: 14751386.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    218. Determining variables for repeat prostate biopsy. Prostate Cancer Prostatic Dis. 2004; 7(2):93-8. Busby JE, Evans CP. PMID: 14993898.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    219. What's hot in the prostate? Prostate Cancer Prostatic Dis. 2004; 7(4):273-6. Gleave M, Evans CP. PMID: 15592439.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    220. The management of stage T1 grade 3 transitional cell carcinoma of the bladder. BJU Int. 2003 Sep; 92(4):345-8. Evans CP, Busby JE. PMID: 12930415.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    221. Long-term safety and efficacy of tamsulosin for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia. J Urol. 2003 Aug; 170(2 Pt 1):498-502. Narayan P, Evans CP, Moon T. PMID: 12853808.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCTClinical Trials
    222. Is bladder biopsy necessary at three or six months post BCG therapy? Urol Oncol. 2003 May-Jun; 21(3):207-9. Highshaw RA, Tanaka ST, Evans CP, deVere White RW. PMID: 12810207.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    223. Hand-assisted laparoscopic vs the open (flank incision) approach to radical nephrectomy. BJU Int. 2003 Mar; 91(4):341-4. Busby E, Das S, Rao Tunuguntla HS, Evans CP. PMID: 12603411.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    224. What's hot in the prostate?. Prostate Cancer and Prostatic Diseases. 2003 Mar 1; 6(1):2-5. Gleave GM, Evans EC. .
      View in: Publisher Site   Mentions:
    225. Does retroperitoneal lymphadenectomy for testicular germ cell tumor require a different approach in the presence of horseshoe kidney? J Urol. 2003 Feb; 169(2):503-6. Evans CP, Tunuguntla HS, Saffarian AR, Wood CG. PMID: 12544297.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    226. What's hot in the prostate? Prostate Cancer Prostatic Dis. 2003; 6(3):200-3. Gleave M, Evans CP. PMID: 12970721.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    227. Angiogenesis is not mediated by prostate cancer neuropeptides. Angiogenesis. 2003; 6(4):289-93. Busby JE, Shih SJ, Yang JC, Kung HJ, Evans CP. PMID: 15166497.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    228. What's hot in the prostate? Prostate Cancer Prostatic Dis. 2003; 6(4):268-71. Gleave M, Evans CP. PMID: 14663465.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    229. Elements regulating angiogenesis and correlative microvessel density in benign hyperplastic and malignant prostate tissue. Prostate Cancer Prostatic Dis. 2003; 6(2):131-7. Shih SJ, Dall'Era MA, Westphal JR, Yang J, Sweep CG, Gandour-Edwards R, Evans CP. PMID: 12806371.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    230. Application of a yeast assay to detect functional p53 mutations in archival prostate cancer tissue. Cancer Biother Radiopharm. 2002 Dec; 17(6):657-64. Shi XB, Di Mauro SM, Highshaw R, Deitch AD, Evans CP, Gumerlock PH, deVere White RW. PMID: 12537669.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansAnimals
    231. What's hot in the prostate. Prostate Cancer and Prostatic Diseases. 2002 Dec 1; 5(4):248-251. Gleave GM, Evans EC. .
      View in: Publisher Site   Mentions:
    232. Initial report of bladder carcinoma following combined bladder-drained pancreas and kidney transplantation. Clin Transplant. 2002 Oct; 16(5):383-6. Highshaw RA, Tunuguntla HS, Perez RV, Gandour-Edwards R, Evans CP. PMID: 12225437.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    233. Minimally invasive therapies for benign prostatic hyperplasia. World J Urol. 2002 Sep; 20(4):197-206. Tunuguntla HS, Evans CP. PMID: 12215846.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    234. Follow-up surveillance strategies for genitourinary malignancies. Cancer. 2002 Jun 01; 94(11):2892-905. Evans CP. PMID: 12115377.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    235. Innovators in Urology, 4th International Meeting. 9-11 March 2002, Miami, Florida, USA. Abstracts. Prostate Cancer Prostatic Dis. 2002; 5 Suppl 1:S1-39. PMID: 12497009.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    236. Management of prostatitis. Prostate Cancer Prostatic Dis. 2002; 5(3):172-9. Gurunadha Rao Tunuguntla HS, Evans CP. PMID: 12496977.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    237. Can single dose preoperative intrathecal morphine sulfate provide cost-effective postoperative analgesia and patient satisfaction during radical prostatectomy in the current era of cost containment? Prostate Cancer Prostatic Dis. 2002; 5(3):226-30. Eandi JA, de Vere White RW, Tunuguntla HS, Bohringer CH, Evans CP. PMID: 12496986.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    238. What's hot in the prostate? Prostate Cancer Prostatic Dis. 2002; 5(3):168-71. Gleave M, Evans C. PMID: 12496976.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    239. Signal transduction-mediated regulation of urokinase gene expression in human prostate cancer. Biochem Biophys Res Commun. 2001 Nov 02; 288(3):521-7. Eandi JA, Yang JC, Evans CP. PMID: 11676474.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    240. Regulation of u-PA gene expression in human prostate cancer. Int J Cancer. 2001 Nov 01; 94(3):390-5. Evans CP, Stapp EC, Dall'Era MA, Juarez J, Yang JC. PMID: 11745419.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    241. Decreased prostate cancer cell migration by inhibition of the insulin-like growth factor II/Mannose-6-Phosphate receptor. Urol Oncol. 1997 Sep-Dec; 3(5-6):166-70. Evans CP, Elfman F, Cunha G, Shuman MA. PMID: 21227140.
      View in: PubMed   Mentions: 3     Fields:    
    242. Inhibition of prostate cancer neovascularization and growth by urokinase-plasminogen activator receptor blockade. Cancer Res. 1997 Aug 15; 57(16):3594-9. Evans CP, Elfman F, Parangi S, Conn M, Cunha G, Shuman MA. PMID: 9270033.
      View in: PubMed   Mentions: 8     Fields:    Translation:Animals
    243. The proportional decrease in prostate specific antigen level best predicts the duration of survival after hormonal therapy in patients with metastatic carcinoma of the prostate. Br J Urol. 1996 Sep; 78(3):426-31. Evans CP, Gajendran V, Tewari A, Aslam K, Juster R, Gange S, Eason A, Narayan P. PMID: 8881955.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    244. What to do if the lymph nodes are positive. Semin Urol Oncol. 1996 May; 14(2):96-102. Evans CP, Swanson DA. PMID: 8734737.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    245. A randomized study comparing visual laser ablation and transurethral evaporation of prostate in the management of benign prostatic hyperplasia. J Urol. 1995 Dec; 154(6):2083-8. Narayan P, Tewari A, Aboseif S, Evans C. PMID: 7500464.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    246. The fate of the iatrogenic retroperitoneal stone. J Urol. 1993 Sep; 150(3):827-9. Evans CP, Stoller ML. PMID: 8345593.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    247. Urinary type IV collagenase: elevated levels are associated with bladder transitional cell carcinoma. Cancer Epidemiol Biomarkers Prev. 1992 Sep-Oct; 1(6):467-74. Margulies IM, Höyhtyä M, Evans C, Stracke ML, Liotta LA, Stetler-Stevenson WG. PMID: 1302559.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCells
    248. An autocrine motility factor secreted by the Dunning R-3327 rat prostatic adenocarcinoma cell subtype AT2.1. Int J Cancer. 1991 Aug 19; 49(1):109-13. Evans CP, Walsh DS, Kohn EC. PMID: 1874563.
      View in: PubMed   Mentions: 7     Fields:    Translation:AnimalsCells
    249. Flow cytometry of fine needle aspirations of the Sprague-Dawley rat testis: defining normal maturation and the effects of multiple biopsies. J Urol. 1991 Aug; 146(2 ( Pt 2)):620-3. Skoog SJ, Evans CP, Hayward IJ, Griffin JL, Hitchcock CL. PMID: 1861314.
      View in: PubMed   Mentions:    Fields:    Translation:Animals
    250. Suprarenal occurrence of an adenomatoid tumor. J Urol. 1988 Feb; 139(2):348-9. Evans CP, Vaccaro JA, Storrs BG, Christ PJ. PMID: 3339740.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    Christopher's Networks
    Concepts (638)
    Derived automatically from this person's publications.
    _
    Co-Authors (105)
    People in Profiles who have published with this person.
    _
    Similar People (60)
    People who share similar concepts with this person.
    _
    Same Department
    Search Department
    _